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Background: Tumour response endpoints, such as overall response rate (ORR) and complete response 21 
(CR), are increasingly used in cancer trials. However, the validity of response-based surrogates is 22 
unclear. This systematic review summarises meta-analyses assessing the association between response-23 
based outcomes and overall survival (OS), progression-free survival (PFS) or time-to-progression 24 
(TTP). 25 
Methods: Five databases were searched to March 2019. Meta-analyses reporting correlation or 26 
regression between response-based outcomes and OS, PFS or TTP were summarised. 27 
Results: The systematic review included 63 studies across 20 cancer types, most commonly non-small 28 
cell lung cancer (NSCLC), colorectal cancer (CRC) and breast cancer. The strength of association 29 
between ORR or CR and either PFS or OS varied widely between and within studies, with no clear 30 
pattern by cancer type. The association between ORR and OS appeared weaker and more variable than 31 
that between ORR and PFS, both for associations between absolute endpoints and associations between 32 
treatment effects.  33 
Conclusions: This systematic review suggests that response-based endpoints such as ORR and CR may 34 
not be reliable surrogates for PFS or OS. Where it is necessary to use tumour response to predict 35 
treatment effects on survival outcomes, it is important to fully reflect all statistical uncertainty in the 36 
surrogate relationship. 37 
  38 
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Introduction  39 
Decisions about the use of new and existing health technologies should ideally be informed by estimates 40 
of treatment effects derived from high quality randomised controlled trials (RCTs) which measure 41 
patient-relevant endpoints over a clinically appropriate timeframe. Such “final” endpoints typically 42 
involve the measurement of health benefits which reflect aspects of the disease and its treatment which 43 
are important to patients (and potentially also their carers) and which relate to “how the patient feels, 44 
functions or survives.”1 In the context of advanced/metastatic cancer, the key matter of concern is often 45 
whether the use of a given heath technology leads to improvements in overall survival (OS; a final 46 
endpoint) compared to existing standard treatments. However, the estimation of treatment effects on 47 
OS may be subject to numerous problems, including: potential confounding resulting from the use of 48 
post-progression treatments, insufficient study follow-up resulting in data immaturity, or simply that 49 
data on OS have not been collected. In such instances, determining the impact of health technologies 50 
becomes more challenging and may rely on the use of surrogate endpoints to substitute for, and predict, 51 
a final patient-relevant clinical outcome.2 Potentially relevant surrogate endpoints vary according to 52 
tumour type and site, but commonly include progression-free survival (PFS), time to progression (TTP), 53 
and response-based outcomes, which may include overall response rate (ORR), different levels of 54 
response (e.g. complete response [CR],  partial response [PR] or very good partial response [VGPR]) 55 
and duration of response (DoR). These surrogate endpoints are often considered attractive as they 56 
typically require smaller sample sizes, occur faster and are less expensive to collect in clinical trials 57 
compared with final outcomes, thereby reducing costs associated with data collection and expediting 58 
the time required for bringing new technologies to market. 59 
It has been recognised in the literature that the reliance on surrogates may lead to invalid conclusions 60 
regarding the net health effects of technologies, which in turn, have the potential to lead to patient 61 
harm.3 Much of the published literature around the use of surrogate endpoints has focussed on the 62 
development and application of frameworks for their validation.4,5 In his seminal paper, Prentice4 put 63 
forward stringent criteria for the validation of surrogate endpoints in Phase III trials. In general terms, 64 
these criteria require that the surrogate endpoint must be a correlate of the net effect of treatment on the 65 
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final clinical outcome – in other words, there must be a single pathway from the treatment to the true 66 
endpoint which is mediated exclusively by the surrogate endpoint.6 Applied surrogate validation studies 67 
commonly adopt a meta-analytic (meta-regression) approach based on multiple studies in order to 68 
assess whether the apparent relationship between the surrogate and the final endpoint remains constant 69 
in the presence of various sources of heterogeneity, such as differences in patient population, study 70 
design and treatments received.5 71 
Based on the NIH Biomarkers Definition Working Group’s preferred terms and definitions7 and the 72 
2001 Journal of the American Medical Association (JAMA) User’s Guide,8 Taylor and Elston9 73 
proposed a hierarchy of levels of surrogate validation. Level 3 of the hierarchy relates to biological 74 
plausibility – this is the weakest form of validation and is typically based on pathophysiological studies 75 
and/or an understanding of the disease process. Level 2 requires the presence of a consistent association 76 
between the surrogate outcome and the final endpoint; this may be assessed using observational studies 77 
or arm-based analyses of trials which have measured both the surrogate and the final outcome. This 78 
level of validation requires an assessment of the individual-level (absolute) association between 79 
endpoints, and is usually undertaken using correlation analysis. Level 1 of the hierarchy represents the 80 
strongest level of surrogate validation: in order to achieve this level of validation, the treatment effect 81 
on the surrogate must correspond to the treatment effect on the final outcome. Demonstrating this level 82 
of validity requires an analysis of correlation in terms of treatment effects between arms based on data 83 
from RCTs (trial-level association). Other validation frameworks have been proposed to assess the 84 
strength of association between surrogate and final endpoints. These include the criteria proposed by 85 
the German Institute of Quality and Efficiency in Health Care10 (IQWiG; based on the treatment effect 86 
association only) and the Biomarker-Surrogate Evaluation Schema criteria11 (BSES2; based on both 87 
absolute and treatment effect associations). These frameworks differ in terms of the types of analyses 88 
and the strength of the relationship required to determine the reliability of the surrogate. 89 
This systematic review summarises published meta-regression studies reporting correlation and 90 
regression analyses for the strength of the association between response-based outcomes and PFS, TTP 91 
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or OS in (primarily) advanced or metastatic cancer, across any tumour site, in order to assess whether 92 
response-based outcomes may be considered as valid surrogates for PFS, TTP or OS. 93 
 94 
Methods 95 
Inclusion and exclusion criteria 96 
Inclusion was restricted to articles reporting meta-analyses or meta-regressions across multiple studies, 97 
and reporting the strength of association between response outcomes (ORR, CR, PR, VGPR or DoR) 98 
and either PFS, TTP or OS. The included meta-regressions could themselves include RCTs and/or 99 
single-arm studies. However, individual reports analysing single trials or single cohorts were excluded 100 
from this review. Included meta-analyses could report absolute associations and/or treatment effect 101 
associations. These associations had to be reported as a correlation coefficient (e.g. Pearson r or 102 
Spearman rs) and/or a coefficient of determination (R
2) between relevant outcomes. 103 
Studies of any cancer and any treatment were included. The review focussed mainly on studies of 104 
advanced or metastatic cancers (and/or treatment with palliative intent), as these studies were more 105 
likely to report PFS and OS. However, studies reporting relevant outcomes were included even where 106 
the stage was not specifically restricted to advanced/metastatic disease for all patients or where this was 107 
unclear (this applied particularly to haematological cancers). Studies were excluded if they explicitly 108 
referred to adjuvant or neo-adjuvant treatment, or treatments which are given with curative intent. 109 
Studies were only included if they were written on English or contained sufficient detail in English. 110 
The review protocol is registered on PROSPERO with registration number CRD42019127606. 111 
Search strategy 112 
Five databases (MEDLINE, EMBASE, Web of Science, the Cochrane Database of Systematic Reviews 113 
and CINAHL) were searched from inception to March 2019. Search terms included: cancer terms AND 114 
response terms AND terms for PFS, TTP and/or OS AND terms for regression, correlation, prediction, 115 
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association or relationship AND terms for endpoint and/or surrogate. Search results were limited to the 116 
English language and to studies undertaken in humans. The MEDLINE search strategy is provided in 117 
Supplementary Information 1. In addition, a citation search was undertaken based on two existing meta-118 
reviews of surrogate relationships; this identified studies which have cited any of the 48 articles included 119 
in the review by Fischer et al. (2016)12 and/or any of the 19 articles included in the review by Davis et 120 
al. (2012).13 In addition, relevant existing meta-reviews, including Fischer et al. (2016),12 Davis et al. 121 
(2012),13 Savina et al. (2018),14 Haslam et al. (2019)15 and any reviews identified during searching, 122 
were checked for relevant studies. 123 
Scoring the strength of association: IQWiG and BSES2 scoring 124 
In this review, two sets of published criteria were used to assess the strength of association between 125 
surrogate and final endpoints: the IQWiG criteria10 and the BSES2 criteria.11  126 
The IQWiG criteria10 are based on the correlation coefficient (r) for the treatment effect association. 127 
Where r was not reported, it was calculated as the square-root of R2, if available. As the Medium score 128 
bracket was not clearly defined, slight modifications were made to the IQWiG criteria based on the 129 
approach used in the previous review by Savina et al.14 (Supplementary Table 1). The IQWiG score 130 
was generated based on the magnitude of r, irrespective of its sign (i.e. a negative correlation could 131 
generate a high score). The IQWiG criteria were scored as follows: High (lower confidence interval of 132 
r is ≥ 0.85); Medium+ (r ≥ 0.85 with no reported confidence interval or r ≥ 0.85 with wide confidence 133 
intervals [lower limit <0.85]); Medium (0.85 > r ≥ 0.7 and upper confidence interval of r is ≥ 0.7 and 134 
lower confidence interval of r is < 0.85, or 0.85 > r ≥ 0.7 with no reported confidence interval); or Low 135 
(upper confidence interval of r is < 0.7 or r < 0.7 with no reported confidence interval).  136 
The BSES2 criteria11 require R2 values for both the absolute and treatment effect associations. Where 137 
R2 was not reported, it was calculated as the square of r, if available. BSES2 criteria were used as an 138 
adaptation from the original BSES criteria, as described in Savina et al. (2018).14 The original BSES 139 
criteria require R2 for both individual and treatment effect associations and a value for the surrogate 140 
threshold effect (STE). Since so few articles report STE, this review used BSES2, which does not 141 
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require the STE. The BSES2 criteria were scored as follows: Excellent (R2 [treatment effect] ≥ 0.6 and 142 
R2 [absolute] ≥ 0.6); Good (R2 [treatment effect] ≥ 0.4 and R2 [absolute] ≥ 0.4); Fair (R2 [treatment 143 
effect] ≥ 0.2 and R2 [absolute] ≥ 0.2); Poor (R2 [treatment effect] < 0.2 and/or R2 [absolute] < 0.2). 144 
Further details on the IQWiG and BSES2 scoring systems are provided in Supplementary Tables 1 and 145 
2. 146 
 147 
Study selection and data extraction 148 
Titles and abstracts of articles retrieved by the search were examined by one reviewer and a subset were 149 
checked by a second reviewer early in the process, followed by a discussion to ensure consistency in 150 
the selection decisions. Full texts were examined by one reviewer and a subset were checked by a 151 
second reviewer, with any discrepancies resolved through discussion. 152 
Data were extracted by one reviewer and all data were checked by a second reviewer. Data were 153 
extracted relating to study design, participant characteristics, surrogate and final endpoints analysed, 154 
methods for correlation and regression, and results including absolute associations, associations 155 
between treatment effects, STE and regression equations. 156 
Data synthesis 157 
Data were presented in a narrative synthesis. Plots were constructed to illustrate the reported 158 
associations within each study. Some of the included meta-regression studies reported multiple 159 
subgroup analyses with differing results. Therefore, each horizontal row in the plots illustrates the range 160 
of reported associations across all subgroup analyses within a single meta-regression study. Where an 161 
included meta-regression study reported on more than one cancer type, these are shown on separate 162 
rows on the plots. 163 
For associations between absolute values of endpoints, the plots show the range of correlation 164 
coefficients per study, across all subgroup analyses. All types of correlation coefficient were included, 165 
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e.g. Pearson r and Spearman rs. If no correlation coefficient was reported, then Pearson r was calculated 166 
as the square-root of R2, if available. 167 
For associations between treatment effects, the plots show the range of regression coefficients of 168 
determination (R2) per study, across all subgroup analyses. The plots include both adjusted and 169 
unadjusted R2 values, as well as values from weighted and unweighted regressions. For studies in which 170 
R2 was not reported, this was calculated as the square of the Pearson r correlation coefficient, if 171 
available. R2 was not calculated from other correlation coefficients such as Spearman, or where the 172 
method of correlation was unclear. 173 
Quality assessment 174 
Included meta-regression studies were assessed for methodological quality based on key criteria from 175 
the AMSTAR-216 and ReSEEM17 checklists most relevant to our review. 176 
Results 177 
Number of included meta-regression studies 178 
The literature search generated 2,829 citations (Figure 1), of which 2,630 were excluded during the 179 
review of titles and abstracts and a further 135 excluded during the review of full texts. In total, 63 180 
studies (within 64 references) were included in the review.18-81 181 
Characteristics of included meta-regression studies 182 
Summaries of study characteristics and reported data types are provided in Supplementary Tables 3 and 183 
4 respectively, while full details of study characteristics for each of the 63 included studies are provided 184 
in Supplementary Table 5. 185 
The most commonly reported surrogate relationships were ORR to OS (57 studies), ORR to PFS (22 186 
studies), CR to OS (8 studies) and CR to PFS (7 studies). Other response outcomes (DoR, PR, 187 
VGPR/CR) were only reported in 1-2 studies each. Twenty different cancer types were analysed, the 188 
most common being NSCLC (16 studies), CRC (10 studies), various solid tumours (8 studies) and 189 
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breast cancer (5 studies). Disease stage was advanced/metastatic in 43 studies and unclear in 9 studies, 190 
while the remainder (11 studies) gave other descriptions mostly indicating advanced, extensive or 191 
recurrent disease. Treatment was first-line in 23 studies, later lines or combinations of lines in 32 192 
studies, and not reported in 8 studies. Treatment type was chemotherapy in 21 studies, immune 193 
checkpoint inhibitors in 9 studies, targeted therapy in 8 studies, and various other treatment 194 
combinations in the remainder. 195 
The various meta-regressions included between 4 and 191 primary studies and between 407 and 44,125 196 
patients each. The majority of meta-regressions (N=44) included only RCTs, while 17 included both 197 
RCTs and single-arm studies and 2 included only single-arm studies. Most meta-regressions (N=58) 198 
analysed aggregate data (e.g. medians or other summary measures per study arm), whilst 5 analysed 199 
individual patient data (IPD). Across all meta-regressions, 32 reported absolute (individual-level) 200 
associations, 38 reported treatment effect (trial-level) associations, and only 4 reported the STE. 201 
 202 
Methodological quality of included meta-regression studies 203 
Methodological quality of the included studies is shown in Supplementary Table 6. All studies had clear 204 
inclusion criteria; 65% reported a comprehensive literature search; and 98% reported a correlation 205 
coefficient or R2 value (the one study not reporting these was included as it reported a regression slope). 206 
However, only 27% reported duplicate study selection; 48% reported duplicate data extraction or 207 
checking; and 13% reported a risk of bias assessment of included studies. In addition, only 37% 208 
explored heterogeneity through subgroup analyses, and only 40% reported confidence intervals around 209 




Results of included studies 212 
The reported associations between surrogate and final endpoints are summarised in Table 1 and 213 
illustrated in Figure 2 to Figure 5. Full results for each included meta-regression study are provided in 214 
Supplementary Table 7 (for absolute associations) and Supplementary Table 8 (for treatment effect 215 
associations). 216 
Absolute (individual-level) correlation and regression 217 
The range of absolute (individual-level) correlation coefficients is summarised in Table 1 and illustrated 218 
in Figure 2 (for the association between ORR and PFS) and Figure 3 (for the association between ORR 219 
and OS). Some of the included meta-regression studies reported multiple subgroup analyses with 220 
differing results. Therefore, each horizontal row in the plots illustrates the range of correlation 221 
coefficients across all subgroup analyses within a single meta-regression study. Where an included 222 
meta-regression reported on more than one cancer type, these are shown on separate rows on the plots. 223 
It is worth noting that the included meta-regression studies differed in terms of various factors, such as 224 
the number of included primary studies (shown as N on the plots), treatment type, line of treatment and 225 
precise clinical population (full details in Supplementary Table 7).  226 
ORR and PFS (or TTP): The reported correlation coefficients (Pearson r or Spearman rs) between 227 
absolute ORR and PFS ranged from -0.72 to 0.96, based on multiple analyses within 12 studies across 228 
10 cancer types44,45,52,54,55,59,62,63,65,66,72,78 (Figure 2 and Table 1). Across those studies which report only 229 
a single analysis, the correlation coefficient was generally above 0.60; however, some estimates were 230 
lower. Confidence intervals around the correlation coefficients were rarely reported. Few separate meta-231 
regressions reported on the same tumour site, hence it is difficult to assess whether ORR may be a more 232 
reliable surrogate in certain cancer types than others. One study reported on ORR and TTP (gastric 233 
cancer; correlation rs = 0.41 to 0.56 across subgroup analyses, not shown on the plot).
42  234 
ORR and OS: The reported correlation coefficients between absolute ORR and OS ranged from -0.40 235 
to 1.00, based on 27 studies across 15 cancer types18,43,19,20,35,37,38,42,45,49-52,59-66,68,70-72,75,78 (Figure 3 and 236 
Table 1). Confidence intervals around the correlation coefficients, where reported, were generally fairly 237 
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wide. The majority of correlation coefficients were above 0.40; however, several estimates were lower. 238 
Neither the correlation coefficients reported from multiple analyses within the same study, nor those 239 
reported across separate studies, suggested a clear pattern by cancer type.  240 
CR and PFS or OS: The correlation coefficients between absolute CR and PFS in two studies of small-241 
cell lung cancer (SCLC)59 and non-Hodgkin’s lymphoma (NHL)81 ranged from 0.22 to 0.83, while the 242 
correlation coefficients between absolute CR and OS ranged from -0.04 to 0.62, based on 3 studies of 243 
NSCLC,49 SCLC59 and gastroesophageal cancer61 (Table 1).  244 
PR and PFS or OS: The correlation coefficient between absolute PR and PFS ranged from 0.35 to 0.70 245 
across subgroup analyses within one study of SCLC,59 while the highest correlation coefficient between 246 
absolute PR and OS ranged from 0.29 to 0.66 in the same study59 (Table 1). 247 
DoR and PFS or OS: No studies reported on the absolute association between DoR and PFS or OS. 248 
Treatment effect (trial-level) correlation and regression 249 
The range of treatment effect (trial-level) R2 values is summarised in Table 1 and illustrated in Figure 250 
4Figure 4 (for the association between ORR and PFS) and Figure 5 (for the association between ORR 251 
and OS). Each horizontal row in the plots illustrates the range of R2 values across all subgroup analyses 252 
within a single meta-regression study. Where an included meta-regression reported on more than one 253 
cancer type, these are shown separately on the plots. It is worth noting that the meta-regressions differed 254 
in terms of the number of included primary studies (shown as N on the plots), treatment type, line of 255 
treatment and precise clinical population (full details in Supplementary Table 8). 256 
ORR and PFS: The regression R2 values for the treatment effect association between ORR and PFS 257 
ranged from 0.18 to 0.94, based on 9 studies across 4 cancer types: NSCLC,21,22,45,67,77 ovarian 258 
cancer,27,72 colorectal cancer26,77 and various solid tumours67,77,79 (Figure 4 and Table 1). The majority 259 
of R2 values were above 0.40. The R2 values reported from multiple analyses within the same study, 260 
and those reported across separate studies, did not suggest a clear pattern by cancer type. Confidence 261 
intervals around the R2 values, where reported, were generally fairly wide. 262 
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ORR and OS: The regression R2 values for the treatment effect association between ORR and OS 263 
ranged from -0.08 to 0.84, based on 31 studies across 11 cancer types21-23,25-32,34,36,37,39-41,45-47,53,56-264 
58,60,63,67,73,74,77,79 (Figure 5 and Table 1). With the exception of one analysis,77 all R2 values were below 265 
0.60. The R2 values reported from multiple analyses within the same study, and those reported across 266 
separate studies, did not suggest a clear pattern by cancer type. Confidence intervals around the R2 267 
values, where reported, were generally wide.  268 
CR and PFS or OS: The regression R2 for the treatment effect association between CR and PFS ranged 269 
from 0.45 to 0.93 across subgroup analyses within one study of NHL,69 while the regression R2 for the 270 
treatment effect association between CR and OS within two studies of breast cancer36 and SCLC34 271 
ranged from 0.05 to 0.48 (Table 1). 272 
PR and PFS or OS: No studies reported the treatment effect association between PR and PFS or OS. 273 
DoR and PFS or OS: No studies reported R2 between DoR and OS or PFS. Two studies in colorectal 274 
cancer29 and pancreatic cancer28 reported Spearman correlation coefficients between DoR and OS 275 
ranging from 0.40 to 0.76 (Table 1). 276 
 277 
Influence of clinical and study factors on association 278 
The impact of the following patient and study factors on the association between ORR and OS was 279 
explored: treatment line; treatment type; response criteria; adjustment of OS for crossover and post-280 
progression treatments; and aggregate versus IPD data (Supplementary Table 9). No clear effect on the 281 
association between ORR and OS was identified for any individual factor. However, this analysis was 282 
limited by the small number of publications assessing each factor within each cancer, and the wide 283 
ranges of associations observed for each. 284 
Five of the 63 included meta-analyses analysed IPD rather than aggregate data; two in breast cancer 285 
(Bruzzi 200523 Burzykowski 200824), one in colorectal cancer (Buyse 200025), one in NHL (Shi 201769) 286 
and one in ovarian cancer (Rose 201066). The associations reported in these studies were not noticeably 287 




Regression equations 290 
Regression equations were reported in fourteen studies for the relationship between ORR and OS; of 291 
these, four reported absolute associations42,52,72,76 and ten reported treatment effect associations.31-292 
33,36,41,46,56,58,67,77 Regression equations  were also reported in eight studies for the relationship between 293 
ORR and PFS; of these, four reported absolute associations52,54,72,76 and four reported treatment effect 294 
associations.24,33,67,77 These analyses spanned 10 cancer types. Full details are provided in 295 
Supplementary Tables 10 and 11. There was substantial variation in the effect measures used for both 296 
the surrogate and final outcomes; for example, difference in medians, hazard ratio (HR), odds ratio 297 
(OR), log-transformed or not. None of the included studies attempted to externally validate their 298 
regression equations for the relationship between response and other outcomes. 299 
Surrogate threshold effect (STE) 300 
The STE - the smallest treatment effect on the surrogate that predicts a non-zero treatment effect on the 301 
true endpoint82 - was reported in only four studies (Supplementary Table 12).26,39,69,77 For the 302 
relationship between ORR and PFS, one study77 in various solid tumours reported that a difference in 303 
ORR of 15% would be required to predict a non-zero treatment effect on the HR for PFS. For the 304 
relationship between ORR and OS, two studies in various solid tumours77 and NSCLC39 reported that a 305 
difference in ORR of 21% and 55% respectively would be required to predict a non-zero treatment 306 
effect on the HR for OS, while one study39 also reported that a difference in ORR of 41% would be 307 
required to predict a non-zero treatment effect on the difference in median OS. A further study in 308 
colorectal cancer26 reported that an OR for ORR of 0.28 would be required to predict a non-zero 309 
treatment effect on the OR for OS. Finally, for the relationship between CR and PFS, one study in 310 
NHL69 reported that an OR for CR (at 30 months) of 1.56 would be required to predict a non-zero 311 
treatment effect on the HR for PFS. 312 
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IQWiG and BSES2 scores for strength of association 313 
IQWiG and BSES2 scores for the strength of association between surrogate and final endpoints were 314 
calculated for all reported subgroup analyses with sufficient data; therefore, meta-regression studies 315 
that reported more subgroups are more strongly represented in this analysis. These data are presented 316 
graphically in Supplementary Figures 1 and 2. 317 
In terms of IQWiG scores, of 202 analyses (across 63 studies), 0 (0%) scored high, 15 (7%) scored 318 
medium+, 26 (13%) scored medium, 76 (38%) scored low and 85 (42%) were not evaluable. In terms 319 
of BSES2 scores, of 202 analyses (across 63 studies), 0 (0%) scored excellent, 3 (1%) scored good, 3 320 
(1%) scored fair, 7 (3%) scored poor and 189 (94%) were not evaluable. 321 
 322 
Discussion 323 
This systematic review summarises published meta-regression studies reporting correlation and 324 
regression analyses for the strength of the association between response outcomes and PFS, TTP or OS 325 
across different types of cancer. In total, the review included 63 studies across 20 cancer types. The 326 
most commonly analysed relationships were between ORR and either PFS or OS. 327 
For the association between ORR and PFS, the majority of reported correlation coefficients between 328 
absolute values were above 0.60 (range -0.72 to 0.96). For association between treatment effects on 329 
ORR and PFS, the majority of regression R2 values were above 0.40 (range 0.18 to 0.94). The 330 
association between ORR and OS appeared weaker than that between ORR and PFS; while the majority 331 
of reported correlation coefficients between absolute values were above 0.40, several estimates were 332 
lower (range -0.40 to 1.00).  For association between treatment effects on ORR and OS, all regression 333 
R2 values except one were below 0.60 (range -0.08 to 0.84). 334 
There was no clear pattern by cancer type for either the absolute or treatment effect associations, based 335 
on both multiple analyses within the same study and results across separate studies. Confidence 336 
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intervals around the reported correlation coefficients and R2 values were generally wide and often not 337 
reported. 338 
Strength of association across all subgroup analyses within all included meta-regression studies was 339 
assessed using the IQWiG and BSES2 scoring systems. The majority of analyses were not evaluable 340 
due to lack of required data. Of those analyses that could be scored, scores were relatively low, 341 
suggesting that response-based endpoints may be poor surrogates for OS.  342 
Previous systematic reviews of surrogate endpoints in advanced cancer have been published. Savina et 343 
al and Haslam et al have reported systematic reviews of meta-analyses assessing any endpoint as a 344 
surrogate for OS.14,15 Both of these reviews also assessed the strength of association using surrogate 345 
validation frameworks; both studies used adaptations of the IQwiG framework, and Savina et al also 346 
used the BSES2 framework. These previous reviews generally focussed on the main analyses presented 347 
within individual meta-analyses (usually that with the largest number of patients). Similar to our review, 348 
these previous reviews suggested that response-based outcomes are likely to be poor surrogates for OS. 349 
Our systematic review focusses exclusively on response-based surrogates; it includes a comprehensive 350 
search to identify relevant studies, considers PFS as a potential final endpoint as well as OS, is more up 351 
to date, includes a greater number of studies, and reports results for the full breadth of analyses reported 352 
in the included meta-regression studies compared with these previous reviews. This provides a more 353 
complete picture of the extent of heterogeneity in reported relationships across the full range of meta-354 
analyses across each cancer area. This additional breadth provides a better basis to inform judgements 355 
about the validity of response-based endpoints as a surrogate for PFS or OS. 356 
The review is subject to a number of limitations. The reported data were highly heterogeneous in terms 357 
of effect measure and method of analysis. Therefore, some simplifying assumptions had to be made to 358 
allow the data to be summarised. For example, correlation coefficients were summarised regardless of 359 
method (Pearson, Spearman or other); R2 values were summarised irrespective of whether or not the 360 
regression was weighted and whether or not the R2 was adjusted; and for treatment effect associations, 361 
R2 values were summarised regardless of the effect measure (e.g. HR, OR, difference in medians). In 362 
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addition, only five studies used IPD rather than aggregate data in their analysis; this is a limitation of 363 
the analyses conducted in the majority of meta-reviews. A recent review by Xie et al highlighted wide 364 
variability in reporting standards across surrogate evaluation meta-regression studies; future analyses 365 
should attempt to adhere to current best practice, for example, the reporting of surrogate endpoint 366 
evaluation using meta-analyses (ReSEEM) guidelines in order to improve the quality of these 367 
analyses.17 368 
It should further be noted that whilst meta-regression has been widely used for the purpose of evaluating 369 
the validity of surrogate endpoints in oncology, this method has been criticised as it ignores uncertainty 370 
around the treatment effect on the surrogate outcome (which is treated as a fixed covariate in the 371 
analysis). Newer methods, such as the bivariate random effects meta-analysis (BRMA) model reported 372 
by Bujkiewicz et al,83 provides an approach for both the validation and prediction of surrogate endpoints 373 
within a Bayesian framework. This approach allows for borrowing of information across studies and 374 
fully accounts for all uncertainty surrounding the surrogate relationship. In spite of the generally poor 375 
association between response-based outcomes and final outcomes, there may still be instances in which 376 
generating predictions on the basis of response is necessary; for example, within health economic 377 
models, or more broadly, for decision-making within health technology assessment. In instances where 378 
the surrogate association is weak, this uncertainty would manifest as a wider prediction interval. If such 379 
predictions are necessary, it is therefore important that all uncertainty is reflected in the model. Future 380 
surrogate evaluation studies should consider the use of the BRMA model, rather than conventional 381 
meta-regression, as a means of fully reflecting this uncertainty. 382 
 383 
Conclusions 384 
This systematic review suggests that response-based endpoints such as ORR and CR may not be reliable 385 
surrogates for PFS or OS in cancer treatment. Strength of association varied widely between and within 386 
studies, with no clear pattern by cancer type. The strength of association between ORR and OS appeared 387 
weaker and more variable than that between ORR and PFS, both for associations between absolute 388 
17 
 
endpoints and associations between treatment effects. Whilst there may still be value in using response 389 
outcomes as a means of predicting final outcomes such as OS, it is important that those predictions are 390 
made on the basis of models which fully reflect the uncertainty around the treatment effect on the 391 
surrogate outcome. 392 
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Figure legends 682 
Figure 1: PRISMA flow diagram for study inclusion 683 
Figure 2: Correlation (r or rs) between absolute (individual-level) values of ORR and PFS 684 
Figure 3: Correlation (r or rs) between absolute (individual-level) values of ORR and OS 685 
Figure 4: Regression R2 between treatment effects (trial-level) for ORR and PFS 686 





Figure 1: PRISMA flow diagram for study inclusion 690 
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Table 1: Summary of absolute correlation coefficients and treatment effect R
2
 values 693 
Surrogate 
relationship 
Range of absolute (individual-level) correlations Range of treatment effect (trial-level) R2 values 
N 
studies 
Cancer types and refs Range of r or rs 




Cancer types and refs Range of R2 across 
studies and 
subgroup analyses 
ORR to PFS 12 NSCLC,45,65,78 ovarian,66,72 RCC,63 
NHL,54 SCLC,59 MM,55 CRC,52 CUP,62  
NET,44 various65,78 
-0.72 to 0.96 9 NSCLC,21,22,45,67,77 ovarian,27,72 
various,67,77,79 CRC26,77 
0.18 to 0.94 
ORR to TTP 1 Gastric42 0.41 to 0.56 0  - 
ORR to OS 27 NSCLC,49,50,65,68,71,45,78 CRC,35,52,75 
ovarian,66,72 breast,51,64 gastric,42,70 
various,65,60,78 pancreatic,37 RCC,18,63 
gastroesophageal,61 urothelial,18,19 
AML,20 SCLC,59 glioblastoma,38 CUP,62 
NET43 




RCC,32,63 breast,23,36 ovarian,27 
prostate,30 BTC,56 STC74 
-0.08 to 0.84 
CR to PFS 2 SCLC,59 NHL81 0.22 to 0.83 1 NHL69 0.45 to 0.93 
CR to OS 3 NSCLC,49 SCLC,59 gastroesophageal61 -0.04 to 0.62 2 Breast,36 SCLC34 0.05 to 0.48 
PR to PFS 1 SCLC59 0.35 to 0.70 0  - 
PR to OS 1 SCLC59 0.29 to 0.66 0  - 
VGPR/CR to PFS 0  (see footnote)* 0  - 
DoR to PFS 0  - 0  - 
DoR to OS 0  - 0  (see footnote)** 
Notes: Further detail on all studies and outcomes is shown in Appendix 5 and Appendix 6. *One study of MM reported the association between VGPR/CR and PFS 
as adjusted R2=0.64, but this could not be converted to r because it was adjusted.55 **Two studies in CRC29 and pancreatic cancer28 reported Spearman correlation 
coefficients between DoR and OS ranging from 0.40 to 0.76, but these could not be converted to R2 as no Pearson correlation coefficients were reported. 
 
AML, acute myeloid leukaemia; BTC, biliary tract cancer; CR, complete response; CRC, colorectal cancer; CUP, cancer of unknown primary; DoR, duration of 
response; MM, multiple myeloma; NET, neuroendocrine tumour; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell lung cancer; ORR, overall response rate; 
OS, overall survival; PFS, progression-free survival; PR, partial response; RCC, renal cell carcinoma; SCLC, small cell lung cancer; STC, soft tissue sarcoma; TTP, 




Figure 2: Correlation (r or rs) between absolute (individual-level) values of ORR and PFS 695 
  696 
For each study, the plot illustrates the range of correlation coefficients across all subgroup analyses. N represents the number of studies included in each meta-regression. CUP, 697 
cancer of unknown primary; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell lung cancer; ORR, overall response rate; PFS, progression-free survival; SCLC, small 698 
cell lung cancer.  699 
28 
 
Figure 3: Correlation (r or rs) between absolute (individual-level) values of ORR and OS 700 
  701 
For each study, the plot illustrates the range of correlation coefficients across all subgroup analyses. N represents the number of studies included in each meta-regression. 702 
AML, acute myeloid leukaemia; CUP, cancer of unknown primary; NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival;  SCLC, small cell 703 
lung cancer.  704 
29 
 
Figure 4: Regression R2 between treatment effects (trial-level) for ORR and PFS 705 
  706 
For each study, the plot illustrates the range of correlation coefficients across all subgroup analyses. N represents the number of studies included in each meta-regression. 707 
NSCLC, non-small cell lung cancer; ORR, overall response rate; PFS, progression-free survival.  708 
30 
 
Figure 5: Regression R2 between treatment effects (trial-level) for ORR and OS 709 
  710 
For each study, the plot illustrates the range of correlation coefficients across all subgroup analyses. N represents the number of studies included in each meta-regression. 711 
NSCLC, non-small cell lung cancer; ORR, overall response rate; OS, overall survival; SCLC, small cell lung cancer. 712 
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Supplementary Information 1: MEDLINE search strategy 
Search Strategy (March 2019): 
1     *Neoplasms/ 
2     (cancer$ or neoplasm$ or tumour$ or tumour$ or malignan$ or oncology or lymphoma$ or sarcoma$ 
or melanoma$ or myeloma$ or carcinoma$).tw. 
3     1 or 2 
4     tumour response$.tw. 
5     tumour response$.tw. 
6     objective response$.tw. 
7     ORR.tw. 
8     "duration of response$".tw. 
9     dor.tw. 
10     response rate$.tw. 
11     complete response$.tw 
12     overall response$.tw 
13     4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 
14     3 and 13 
15     Regression analysis/ 
16     regression.tw. 
17     relationship.tw. 
18     correlation.tw. 
19     prediction.tw. 
20     association.tw. 
21     15 or 16 or 17 or 18 or 19 or 20 
22     14 and 21 
23     endpoint$.tw. 
24     end point$.tw. 
25     (surrogate or surrogacy).tw. 
26     23 or 24 or 25 
27     22 and 26 
28     progression-free survival/ 
29     "progression free survival".tw. 
30     "overall survival".tw. 
31     (pfs or os).tw. 
32     "time to progression".tw. 
33     ttp.tw. 
34     28 or 29 or 30 or 31 or 32 or 33 
35     27 and 34 





Supplementary Table 1: IQWiG scoring criteria 
IQWiG Score Criteria (based on r for treatment-effect association)* 
High Lower confidence interval of r is ≥ 0.85 
Medium+ r ≥ 0.85 with no reported confidence interval or r ≥ 0.85 with wide confidence 
intervals (lower limit <0.85)  
Medium 0.85 > r ≥ 0.7 and upper confidence interval of r is ≥ 0.7 and lower confidence 
interval of r is < 0.85, or 0.85 > r ≥ 0.7 with no reported confidence interval 
Low Upper confidence interval of r is < 0.7 or r < 0.7 with no reported confidence interval 
Notes: 
Based on the scoring criteria reported by IQWiG (2011).10 
*r is defined as any correlation parameter for the treatment-effect association, e.g. Pearson, Spearman, Kendall's 
Tau. Where no correlation parameter was reported, if a univariate regression was performed and an R2 value 
attained, then r (Pearson correlation coefficient) was calculated as the square-root of R2. The reported r could be 
for any treatment effect estimate (hazard ratio, difference in medians, etc.); where more than one was reported, 
relative estimates (e.g. hazard ratio, odds ratio) were used in preference to difference in medians. The Medium+ 
category was based on the approach used in Savina et al.14 
 
Supplementary Table 2: BSES2 scoring criteria 
BSES2 score Criteria (based on R
2
 for both treatment effect and individual-level associations)* 
Excellent R2 (treatment effect) ≥ 0.6 and R2 (absolute) ≥ 0.6 
Good R2 (treatment effect) ≥ 0.4 and R2 (absolute) ≥ 0.4 
Fair R2 (treatment effect) ≥ 0.2 and R2 (absolute) ≥ 0.2 
Poor R2 (treatment effect) < 0.2 and/or R2 (absolute) < 0.2 
Notes: 
Based on the scoring criteria reported by Lassere et al. (2012).11 
*R2 is the coefficient of determination for a regression analysis. Where R2 was not reported, it was calculated 
as the square of the Pearson correlation coefficient (r), if available. The reported R2 could be for any treatment 
effect estimate (hazard ratio, difference in medians, etc.); where more than one was reported, relative estimates 




Supplementary Table 3: Summary of study characteristics 1 
Surrogate relationship N Cancer type N Disease stage N Line of treatment N Treatment type N 
ORR to OS 
ORR to PFS 
CR to OS 
CR to PFS 
DoR to OS 
ORR to TTP 
PR to PFS 
PR to OS 
VGPR/CR to PFS 





















































Advanced, locally advanced, 
unresectable or metastatic 
Extensive disease 
Limited or extensive disease 
Advanced or recurrent 
Advanced, locally advanced or 
recurrent 
Relapsed / refractory 
Most stage III/IV 
















All / various 
NR 
1st + 2nd 
2nd 
2nd + subsequent 














Chemo or targeted 
Chemo, immune or targeted 
NR 
Chemo + targeted 
Chemo or immune 
Chemo, hormonal + targeted 
Chemo or biologic 
Cytokine or targeted 
Gemcitabine + chemo or 
targeted 

















Note: Ns may sum to more than total number of studies (N=63) as some studies reported more than one surrogate relationship or cancer type. 
AML, acute myeloid leukaemia; chemo, chemotherapy; CR, complete response; DoR, duration of response; immune, immunotherapy; NR, not reported; NSCLC, 
non-small cell lung cancer; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PR, partial response; SCLC, small cell lung cancer; 
TTP, time to progression; VGPR, very good partial response. 
 2 
Supplementary Table 4: Summary of reported data types 3 
N primary studies per 
meta-regression (range) 
N patients per meta-
regression (range) 
Included study types 
per meta-regression 






4 to 191 407 to 44,125 RCT only (N=44) 
RCT+SA (N=17) 
SA only (N=2) 
AD  (N=58) 
IPD  (N=5) 
N=32 N=38 N=4 
AD, aggregate data; IPD, individual patient data; RCT, randomised controlled trials; SA, single-arm studies; STE, surrogate threshold effect. 
  4 
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Supplementary Table 5: Study characteristics by study 5 





























OS Various 1st Systemic 20† NR RCT + 
SA 
2004-2016 AD NR Y   
Moriwaki 
201656 
Biliary tract ORR OS Advanced 1st Chemo 17† 2040 RCT Up to 2015 AD NR  Y  
Bruzzi 
200523 
Breast ORR OS Metastatic All Chemo 10 2126 RCT 1991-2001 IPD WHO (8), ECOG 
(1), NR (1) 
 Y  
Burzykowsk
i 200824 
Breast ORR PFS 
OS 





OS Metastatic 1st Chemo 42* 9163 RCT 1966-2005 AD NR  Y  
Liu 201651 Breast ORR* OS Metastatic 2nd + 3rd Chemo 24 8617 RCT 1999 to 2014 AD NR Y   
Petrelli 
201464 
Breast ORR OS Metastatic or 
advanced 
1st Targeted + 
chemo 
20† 10138† RCT 2000 to 2012 AD NR Y   
Buyse 
200025 
Colorectal ORR OS Advanced 1st Chemo 25 3791 RCT Collected 
1990-1996 
IPD WHO  Y  
Ciani 201526 
Elia 201833 




All Systemic 33 NR RCT 2003-2013 AD RECIST or 
WHO 





OS Metastatic 1st Bevacizumab + 
chemo 
11 NR RCT 2000-2014 AD RECIST  Y  
Giessen 
201535 
Colorectal ORR OS Metastatic 2nd Chemo 22 10509 RCT 2000-2013 AD RECIST (17), 
WHO (5) 
Y   
Cremolini 
201731 
Colorectal ORR OS Metastatic 2nd Targeted 20* 7571 RCT To 2015 AD NR  Y  
Johnson 
200646 
Colorectal ORR OS Metastatic 1st Chemo 146† 35337† RCT To 2005 AD NR (very few 
RECIST) 
 Y  
Louvet 
200152 
Colorectal ORR PFS 
OS 
Metastatic 1st Various 29 13498 RCT 1990 to 2000 AD NR Y   
Sidhu 
201373 
Colorectal ORR OS Metastatic 1st (most) Chemo +/- 
targeted 
24† 20438† RCT 2000 to 2011 AD NR  Y  
Tang 200775 Colorectal ORR OS Metastatic 1st Chemo 39 18668 RCT 1990 to 2005 AD NR Y Y  
Tsujino 
201077 
Colorectal ORR PFS 
OS 
Advanced NR Targeted 7 NR RCT Up to 2009 AD NR  Y  
Ichikawa 
200642 
Gastric ORR TTP 
OS 
Advanced 1st Chemo 25 4593 RCT NR AD WHO, SWOG, 
RECIST, Japan 
Y   
Shitara 
201470 




AD NR Y   
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OS Advanced 1st + 2nd Targeted 18 7892 RCT Up to 2018 AD RECIST Y   
Han 201438 Glioblastoma ORR OS Unclear Various Various 91† 7125† RCT + 
SA 
1991-2012 AD NR ("standard 
criteria") 







Metastatic Various Chemo, immune 
or targeted 
25 20013† RCT 2003-2016 AD RECIST or 
WHO 







Metastatic Various Chemo or 
targeted 
14 12567† RCT 2003-2013 AD RECIST (11) or 
WHO (3) 





ORR OS Advanced 2nd + 
subsequent 
Various 140 41725 RCT To 2016 AD NR  Y Y 
Hotta 201540 Lung 
(NSCLC) 
ORR OS Advanced Various Targeted 18 7633† RCT 2003-2014 AD NR  Y  













ORR OS Advanced 1st Chemo 191† 44125† RCT To 2005 AD NR (very few 
RECIST) 
 Y  




OS Advanced 1st + 2nd Immune 
checkpoint 
inhibitors 
5† 4803† RCT Up to 2018 AD RECIST Y   
Li 201250 Lung 
(NSCLC) 
ORR OS Advanced 1st + 2nd Targeted 60 9903 RCT + 
SA 
Up to 2011 AD RECIST (52), 
WHO (10) 
















Advanced All Immune 
checkpoint 
inhibitors (PD-
(L)1 or CTLA4) 







Unclear Various Immune 
checkpoint 
inhibitors 
7* 3369* RCT Up to 2017 AD RECIST or 
mWHO 





ORR OS Unclear Various Chemo 42 1935 SA +1 
RCT 
1988-1997 AD WHO Y   
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NR RCT + 
SA 














Advanced NR Targeted 28 6171 RCT + 
SA 
To 2007 AD RECIST (21), 
WHO (9) 












NR Chemo or 
targeted 
35 NR RCT + 
SA 
2006 to 2008 AD NR Y   
Foster 
201134 




1st Chemo 3 RCTs 
(32 
centres) 




ce; PR ≥50% 
reduction 
 Y  
Hotta 200941 Lung (SCLC) ORR OS Extensive 
disease 
1st Chemo 48 8779 RCT 1990-2008 AD WHO (23), 
ECOG (2), 
RECIST (1), 
Japan (1), or NR 
 Y  
Nickolich 
201459 








1st + 2nd + 
maintenance 
Various 66† 8471† RCT + 
SA 














Various 79† 13322† RCT + 
SA 





ORR PFS Advanced Various Systemic 22 1310 RCT + 
SA 
1996-2016 AD RECIST (20), 
WHO (2) 





ORR OS Advanced Various Systemic 20 2530 RCT + 
SA 
1996-2016 AD NR Y   




Unclear 1st Chemo 36† 16103† RCT 1990-2009 AD NR  Y  




Unclear 1st Chemo 15† 5128† RCT 1990-2009 AD NR  Y  
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Various Various 73 6071 RCT + 
SA 
1996 to 2015 AD NR Y   









13 3837 RCT 1990 to 2011 IPD NR (CR= 
disappearance) 
 Y Y 
Zhu 201781 NHL 
(indolent; 
follicular) 
CR PFS Unclear NR Chemo, immune 
or targeted 
13 NR RCT + 
SA 
1993 to 2013 AD NR Y   
Zhu 201781 NHL (mantle 
cell) 
CR PFS Unclear NR Chemo, immune 
or targeted 
NR NR RCT + 
SA 








Advanced 1st Chemo 29 NR RCT 1990-2016 AD WHO (24), 
RECIST (8) 
 Y  





2nd Various 11 407 SA 1994 to 2004 IPD WHO (10), 
RECIST (1) 
Y   
Siddiqui 
201772 















1st Gemcitabine + 
chemo or 
targeted 
36* NR RCT 1997-2014 AD RECIST  Y  
Hamada 
201637 
















 Y  
Colloca 
2016c30 
Prostate ORR OS Metastatic 
(castration-
resistant) 
1st + 2nd Chemo, 
hormonal + 
targeted 












4 1093 RCT + 
SA 
To 2017 AD RECIST Y   
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Renal cell ORR OS Metastatic NR Cytokine or 
targeted 
25* 10943† RCT 1997-2010 AD NR  Y  
Petrelli 
201363 
Renal cell ORR PFS 
OS 





ORR OS Advanced 1st Chemo 27† 6156† RCT 1974 to 2017 AD NR  Y  
Zer 201680 Soft tissue 
sarcoma 
ORR OS Advanced or 
metastatic 
All Systemic 52† 9762† RCT 1974 to 2014 AD NR  Y  




Unclear NR NR 38† NR SA 1997 to 2011 AD RECIST or 
WHO 








9 1699 RCT + 
SA 
To 2017 AD RECIST Y   
Agarwal 
201419 
Urothelial ORR OS Advanced 
(operable or 
metastatic) 
2nd Chemo or 
biologic 
10 560 RCT + 
SA 









27† 10300† RCT 2005-2017 AD RECIST or 
mWHO 









13 6722 RCT 2014 to 2016 AD RECIST  Y  
Nie 201960 Various solid 
tumours 
ORR* OS Advanced or 
recurrent 




43† 15088† RCT + 
SA 







Advanced All Immune 
checkpoint 
inhibitors (PD-
(L)1 or CTLA4) 







Unclear Various Immune 
checkpoint 
inhibitors 
17† 8994† RCT Up to 2017 AD RECIST or 
mWHO 







Advanced NR Targeted 18 NR RCT Up to 2009 AD NR  Y Y 
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NR Chemo or 
targeted 
143† 6974† RCT + 
SA 







Metastatic NR NR 66† NR RCT NR AD NR  Y  
Note: Of the 63 included studies (64 refs), 8 references18,46,48,65,67,77,78,81 appear on 2-3 rows as they report on 2-3 different cancer types. *Calculated from reported data. †Unclear for individual subgroups. 
 
AD, aggregate data; chemo, chemotherapy; CR, complete response; DoR, duration of response; ECOG, Eastern Cooperative Oncology Group; IMWG, International Myeloma Working Group (criteria); 
IPD, individual patient data; mo, months; mWHO, modified World Health Organisation (criteria); NHL, non-Hodgkin’s lymphoma; NR, not reported; NSCLC, non-small cell lung cancer; ORR, overall 
response rate (ORR=PR+CR); OS, overall survival; PFS, progression-free survival; PR, partial response; RCT, randomised controlled trials; RECIST, Response Evaluation Criteria In Solid Tumours; SA, 
single-arm studies; SCLC, small cell lung cancer; STE, surrogate threshold effect; TTP, time to progression; VGPR, very good partial response; WHO, World Health Organisation (criteria). 
  6 
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Supplementary Table 6: Quality assessment of included meta-reviews 7 
Reference Cancer Inclusion criteria 





comprehensive (at least 
2 databases or other 















correlation coefficient (r 
or rs) and/or coefficient 









intervals for r, rs 
or R2) 
Agarwal 201720 AML Y N (PubMed only) U U N Y N N 
Moriwaki 201656 Biliary tract Y Y U Y N Y Y Y 
Bruzzi 200523 Breast Y Y U Y N Y N Y 
Burzykowski 
200824 
Breast Y N U U N Y N Y 
Hackshaw 200536 Breast Y N (Medline only) U U N Y Y N 
Liu 201651 Breast Y Y Y Y N Y Y Y 
Petrelli 201464 Breast Y Y U U N Y N Y 
Buyse 200025 Colorectal Y U U Y N Y N Y 
Ciani 201526 
Elia 201833 
Colorectal Y Y Y Y Y Y Y Y 
Colloca 2016b29 Colorectal Y Y U U N Y N N 
Giessen 201535 Colorectal Y Y U U N Y N Y 
Cremolini 201731 Colorectal Y Y U Y N Y Y N 
Johnson 200646 Colorectal 
Lung (NSCLC) 
Y Y N Y Y Y N N 
Louvet 200152 Colorectal Y U U U N Y N N 
Sidhu 201373 Colorectal Y Y U U N Y Y Y 
Tang 200775 Colorectal Y Y U U N Y N Y 
Tsujino 201077 Colorectal 
Lung (NSCLC) 
Various tumours 
Y N (PubMed only) U Y N Y N N 
Ichikawa 200642 Gastric Y Y U U N Y Y N 
Shitara 201470 Gastric Y Y U U N Y N Y 
Pang 201861 Gastroesophageal Y N (search terms NR) U Y Y Y N N 
Han 201438 Glioblastoma Y Y U U N Y N Y 
Blumenthal 
201722 
Lung (NSCLC) Y N (trials submitted to 
FDA rather than search) 
U U N Y N Y 
Blumenthal 
201521 
Lung (NSCLC) Y N (FDA trials not search) U U N Y Y Y 
12 
 
Reference Cancer Inclusion criteria 





comprehensive (at least 
2 databases or other 















correlation coefficient (r 
or rs) and/or coefficient 









intervals for r, rs 
or R2) 
Hashim 201839 Lung (NSCLC) Y Y Y Y Y Y Y Y 
Hotta 201540 Lung (NSCLC) Y Y U Y N Y Y N 
Ito 201945 Lung (NSCLC) Y Y Y U N Y Y N 
Li 201949 Lung (NSCLC) Y N (search terms NR) U Y Y Y N N 
Li 201250 Lung (NSCLC) Y Y Y Y N Y N N 
Nakashima 201658 Lung (NSCLC) Y Y Y Y Y Y N N 
Ritchie 201865 Lung (NSCLC) 
Various tumours 
Y Y U Y Y Y N Y 
Roviello 201767 Lung (NSCLC) 
Various tumours 
Y Y Y Y N Y Y (for various) Y 
Sekine 199968 Lung (NSCLC) Y Y U U N Y N N 
Shukuya 201671 Lung (NSCLC) Y Y U Y N Y Y N 
Tsujino 200976 Lung (NSCLC) Y Y U U N N (slope only) N N 
Vidaurre 200978 Lung (NSCLC) 
Various 
Y N (trials in 5 journals 
rather than search) 
U Y N Y Y (for various) N 
Foster 201134 Lung (SCLC) Y N (trials by 1 group 
rather than search) 
U U N Y N N 
Hotta 200941 Lung (SCLC) Y Y U Y N Y Y N 
Nickolich 201459 Lung (SCLC) Y N (trials in 1 journal 
rather than search) 
U Y N Y Y N 
Mangal 201855 
(myeloma) 
Multiple myeloma Y Y U U N Y N N 
Imaoka 201944 Neuroendocrine Y Y Y U N Y Y Y 
Imaoka 201743 Neuroendocrine Y Y Y U N Y N Y 
Lee 201148 NHL (aggressive) 
NHL (indolent) 
Y Y U U N Y N Y 
Mangal 201854 
(NHL) 
NHL Y Y U U N Y N N 
Shi 201769 NHL (follicular) Y Y U U N Y Y Y 
Zhu 201781 NHL (follicular) 
NHL (mantle cell) 
Y Y U U N Y N Y 
13 
 
Reference Cancer Inclusion criteria 





comprehensive (at least 
2 databases or other 















correlation coefficient (r 
or rs) and/or coefficient 













Ovarian Y Y Y U N Y Y N 
Rose 201066 Ovarian Y N (trials by 1 group 
rather than search) 
N U N Y N N 
Siddiqui 201772 Ovarian Y Y U Y N Y N N 
Colloca 2016a28 Pancreatic Y N (PubMed only) Y U N Y Y N 
Hamada 201637 Pancreatic Y Y Y Y N Y N Y 
Makris 201753 Pancreatic  
(adenocarcinoma) 
Y N (search terms NR) Y Y N Y N Y 





Y Y U U N Y N N 
Delea 201232 Renal cell Y N (search terms NR) Y U N Y N N 
Petrelli 201363 Renal cell Y Y U Y N Y N N 
Tanaka 201974 Soft tissue 
sarcoma 
Y Y U Y N Y N Y 
Zer 201680 Soft tissue 
sarcoma 
Y Y U Y Y Y N N 
Penel 201462 Unknown primary Y N (Medline only; search 
terms NR) 
U U N Y N N 
Agarwal 201419 Urothelial Y N (search methods NR) U U N Y Y N 
Kaufman 201847 Various tumours Y Y Y Y N Y Y N 
Mushti 201857 Various tumours Y N (FDA trials not search) U U N Y N N 
Nie 201960 Various tumours Y Y Y Y N Y N N 
Wilkerson+Fojo 
200979 
Various tumours Y N (search methods NR) U Y N Y N N 
AML, acute myeloid leukaemia; N, No; NHL, non-Hodgkin’s lymphoma; NR, not reported; NSCLC, non-small cell lung cancer; SCLC, small cell lung cancer; U, Unclear; Y; Yes. 
  8 
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Supplementary Table 7: Absolute correlation and regression results per study 9 
Ref SO FO Cancer Line 
Sub-groups 
Treatment N stds N pts Absolute correlation 
methods 
Correlation  coefficient 










ORR vs. PFS (or TTP) 
Louvet 
200152 
ORR PFS Colorectal 1st Various 29 13498 Spearman (ORR vs. 
med PFS) 
rs=0.66, p<0.0001 LR (ORR vs. 
med PFS) 




ORR TTP Gastric 1st Chemo (any) 12* 2144 Spearman, wtd O(RR 
vs. med TTP) 
rs=0.49, p<0.0001 WLR (ORR 
vs. med TTP) 
  TTP = 1.73 + 
0.09 * ORR 
Ichikawa 
200642 
ORR TTP Gastric 1st Chemo (novel) 8* 1077 Spearman, wtd (ORR 
vs. med TTP) 
rs=0.41, p=0.018       
Ichikawa 
200642 
ORR TTP Gastric 1st Chemo (non-novel) 7* 1067 Spearman, wtd (ORR 
vs. med TTP) 
rs=0.56, p=0.0053       
Ito 201945 ORR PFS Lung 
(NSCLC) 
Various Immune checkpoint 
inhibitors (PD-(L)1) 
6 3752† a) Pearson, wtd 
b) Spearman, wtd 
(ORR vs. med PFS) 
a) r=0.55, p<0.0001 
b) rs=0.33, p<0.0001 
WLR R2 





Ito 201945 ORR PFS Lung 
(NSCLC) 
- Various 




7 1381 a) Pearson, wtd 
b) Spearman, wtd 
(ORR vs. med PFS) 
a) r=0.90, p<0.0001 
b) rs=0.48, p<0.0001 
WLR R2 







ORR PFS Lung 
(NSCLC) 
All Immune checkpoint 
inhibitors (PD-(L)1 or 
CTLA4) 
8 NR Correlation (NR) 
(ORR vs. 6mo PFS) 
r=0.85 (0.63 to 1.06), 
p=NR 
      
Tsujino 
200976 
ORR PFS Lung 
(NSCLC) 
NR Targeted 18* 3790*     LR (ORR vs. 
med PFS) 
R2=NR, p=0.001 Slope 0.072 
Vidaurre 
200978 
ORR PFS Lung 
(NSCLC) 
NR Chemo or targeted 35 NR     Regression 
(NR) (ORR 






ORR PFS Lung 
(SCLC) 
- 1st + 2nd + 
maintenance 
- Limited or 
extensive 
Various 66† 8471† Pearson (ORR vs. 
med PFS) 
r=0.73, p<0.0001       
Nickolich 
201459 
ORR PFS Lung 
(SCLC) 




Various 66† 8471† Pearson (ORR vs. 
med PFS) 
r=0.02, p=0.978       
Nickolich 
201459 
ORR PFS Lung 
(SCLC) 




Various 66† 8471† Pearson (ORR vs. 
med PFS) 
r=0.51, p=0.013       
15 
 
Ref SO FO Cancer Line 
Sub-groups 
Treatment N stds N pts Absolute correlation 
methods 
Correlation  coefficient 













ORR PFS Multiple 
myeloma  
2nd + Various 79† 13322†     WLR adj R2 
(logit ORR vs. 








Various Systemic 22 1310 Pearson (ORR vs. 
med PFS) 
r=0.37 (-0.05 to 0.80), 
p=0.085 








Systemic 6* NR Pearson (ORR vs. 
med PFS) 
r= -0.08 (-0.76 to 0.60), 
p=0.824 








Systemic 16* NR Pearson (ORR vs. 
med PFS) 
r=0.43 (-0.07 to 0.93), 
p=0.095 





Various Cytotoxic 9 arms NR Pearson (ORR vs. 
med PFS) 
r=0.63 (0.03 to 1.22), 
p=0.041 





Various Non-cytotoxic 18 
arms 
NR Pearson (ORR vs. 
med PFS) 
r=0.18 (-0.27 to 0.62), 
p=0.432 





Various Targeted 19 
arms 
NR Pearson (ORR vs. 
med PFS) 
r=0.42 (-0.06 to 0.90), 
p=0.086 





Various Non-targeted 8 arms NR Pearson (ORR vs. 
med PFS) 
r= -0.72 (-1.09 to -0.35), 
p<0.001 




ORR PFS NHL Various Various 73 6071     LR adj R2 
(logit ORR vs. 
log med PFS) 
Adj R2=0.70, 
p=NR 
log (med PFS) = 
1.97 + 0.414 * 
logit (ORR) 
Rose 201066 ORR PFS Ovarian 2nd Various 11 407 a) Pearson 
b) Kendall Tau-b 
(ORR vs. med PFS) 
a) r=0.62, p=0.044 
 
b) r=0.48, p=0.042 
      
Siddiqui 
201772 
ORR PFS Ovarian 2nd + Chemo 39† 9223† a) Pearson, wtd (ORR 
vs. med PFS) 
b) Pearson, unwtd 
(ORR vs. med PFS) 
a) r=0.85, p<0.001 
b) 0.76, p<0.001 
WLR R2 






b) adj R2=0.72, 
p=NR 
med PFS = 2.59 
+ 0.12 * ORR 
Petrelli 
201363 
ORR PFS Renal cell 1st Targeted 6† 3188† Spearman, wtd (ORR 
vs. med PFS) 
rs=0.96, p<0.0001       
Penel 201462 ORR PFS Unknown 
primary 
NR NR 38† NR Pearson via WLR 
(ORR v. med PFS) 
r=0.54, p<0.0001       
Ritchie 
201865 
ORR PFS Various 
solid 
tumours 
All Immune checkpoint 
inhibitors (PD-(L)1 or 
CTLA4) 
20† 10828† Correlation (NR) 
(ORR vs. 6mo PFS) 
r=0.37 (0.06 to 0.95), 
p=NR 
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Ref SO FO Cancer Line 
Sub-groups 
Treatment N stds N pts Absolute correlation 
methods 
Correlation  coefficient 












ORR PFS Various NR Chemo 85 3982*     Regression 
(NR) (ORR 






ORR PFS Various NR Targeted 58 2992*     Regression 
(NR) (ORR 






ORR PFS Various NR Chemo or targeted 143† 6974†     Regression 
(NR) (ORR 




ORR vs. OS 
Agarwal 
201720 
ORR OS Acute 
myeloid 
leukemia 
1st Systemic 20† NR     WLR adj R2 
(logit ORR vs. 




Liu 201651 ORR OS Breast 2nd + 3rd Chemo 24 8617 Spearman (ORR vs. 
med OS) 
rs=0.54 (0.29 to 0.72), 
p<0.0001 
      




Chemo 15* NR Spearman (ORR vs. 
med OS) 
rs=0.62 (0.32 to 0.84), 
p=NR 
      




Chemo 5* NR Spearman (ORR vs. 
med OS) 
rs=0.78 (0.19 to 1.0), 
p=NR 
      
Liu 201651 ORR OS Breast 2nd + 3rd Chemo (taxanes) 21* NR Spearman (ORR vs. 
med OS) 
rs=0.49 (-0.19 to 0.92), 
p=NR 
      
Liu 201651 ORR OS Breast 2nd + 3rd Chemo 
(antimetabolites) 
22* NR Spearman (ORR vs. 
med OS) 
rs=-0.10, p=NR       
Liu 201651 ORR OS Breast - 2nd + 3rd 
- HER2-pos 
Chemo 5* NR Spearman (ORR vs. 
med OS) 
rs=0.96 (0.80 to 1.00), 
p=NR 
      
Liu 201651 ORR OS Breast - 2nd + 3rd 
- HER2-neg 
Chemo 3* NR Spearman (ORR vs. 
med OS) 
rs=1.00, p=NR       
Petrelli 
201464 
ORR OS Breast 1st Targeted + chemo 20† 10138† Spearman, wtd (ORR 
vs. med OS) 
rs=0.61 (0.59 to 0.63), 
p=NR 
      
Giessen 
201535 
ORR OS Colorectal 2nd Chemo 22 10509 Pearson, wtd (log 
odds ORR vs. log 
med OS) 
r=0.58 (0.38 to 0.72), 
p=0.003 
      
Louvet 
200152 
ORR OS Colorectal 1st Various 28* 13284* Spearman (ORR vs. 
med OS) 
rs=0.41, p=0.0009 LR (ORR vs. 
med OS) 
  OS = 10.45 + 
0.088 * ORR 
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Ref SO FO Cancer Line 
Sub-groups 
Treatment N stds N pts Absolute correlation 
methods 
Correlation  coefficient 










Tang 200775 ORR OS Colorectal 1st Chemo 39 18668 Spearman (ORR vs. 
med OS) 
rs=0.59 (0.42 to 0.72), 
p<0.000001 
      
Ichikawa 
200642 
ORR OS Gastric 1st Chemo (any) 25 4593 Spearman, wtd (ORR 
vs. med OS) 
rs=0.45, p<0.0001 WLR (ORR 
vs. med OS) 
  OS = 5.89 + 
0.08 * ORR 
Ichikawa 
200642 
ORR OS Gastric 1st Chemo (novel) 11* 1170 Spearman, wtd (ORR 
vs. med OS) 
rs=0.18, p=0.12       
Ichikawa 
200642 
ORR OS Gastric 1st Chemo (non-novel) 20* 3423 Spearman, wtd (ORR 
vs. med OS) 
rs=0.47, p<0.0001       
Shitara 
201470 
ORR OS Gastric 2nd + 3rd Chemo 64 4286 Spearman (ORR vs. 
med OS) 
rs=0.38 (0.16 to 0.6), 
p=NR 
      
Pang 201861 ORR OS Gastroeso
phageal 
1st + 2nd Targeted 18 7892 Correlation (NR) 
(ORR vs. med OS) 
r=0.86, p<0.0001       
Han 201438 ORR OS Glioblasto
ma 
Various Various 91† 7125†     WLR R2 
(ORR vs. med 
OS) 
R2=0.22 (0.04 to 
0.42), p=NR 
  
Ito 201945 ORR OS Lung 
(NSCLC) 
Various Immune checkpoint 
inhibitors (PD-(L)1) 
6 3752† a) Pearson, wtd 
b) Spearman, wtd 
(ORR vs. med OS) 
a) r= -0.02, p=0.4564 
b) rs= -0.14, p<0.0001 
      
Ito 201945 ORR OS Lung 
(NSCLC) 
- Various 




7 1381 a) Pearson, wtd 
b) Spearman, wtd 
(ORR vs. med OS) 
a) r=0.92, p<0.0001 
b) rs=0.77, p<0.0001 
WLR R2 





Li 201949 ORR OS Lung 
(NSCLC) 
1st + 2nd Immune checkpoint 
inhibitors 
5† 4803† Pearson (ORR vs. 
med OS) 
r=0.52, p=0.28 LR (ORR vs. 
med OS) 
R2=0.27, p=NR   
Li 201250 ORR OS Lung 
(NSCLC) 
1st + 2nd Targeted 60 9903     WLSR R2 







ORR OS Lung 
(NSCLC) 
All Immune checkpoint 
inhibitors (PD-(L)1 or 
CTLA4) 
8 NR Correlation (NR) 
(ORR vs. 12mo OS) 
r=0.66 (0.17 to 1.08), 
p=NR 
      
Sekine 
199968 
ORR OS Lung 
(NSCLC) 
Various Chemo 42 1935 Pearson (ORR vs. 
med OS) 
r=0.62, p<0.001       
Shukuya 
201671 
ORR OS Lung 
(NSCLC) 
All Immune checkpoint 
inhibitors (PD-(L)1) 
10† NR Spearman, wtd (ORR 
vs. med OS) 
rs=0.45, p=0.141       
Shukuya 
201671 
ORR OS Lung 
(NSCLC) 
All Chemo (docetaxel) 22† NR Spearman, wtd (ORR 
vs. med OS) 
rs=0.41, p=0.053       
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Ref SO FO Cancer Line 
Sub-groups 
Treatment N stds N pts Absolute correlation 
methods 
Correlation  coefficient 












ORR OS Lung 
(NSCLC) 







ORR OS Lung 
(NSCLC) 
NR Chemo or targeted 35 NR     Regression 
(NR) (ORR 






ORR OS Lung 
(SCLC) 
- 1st + 2nd + 
maintenance 
- Limited or 
extensive 
Various 66† 8471† Pearson (ORR vs. 
med OS) 
r=0.66, p<0.0001       
Nickolich 
201459 
ORR OS Lung 
(SCLC) 




Various 66† 8471† Pearson (ORR vs. 
med OS) 
r=0.40, p=0.193       
Nickolich 
201459 
ORR OS Lung 
(SCLC) 




Various 66† 8471† Pearson (ORR vs. 
med OS) 





Various Systemic 20 2530 Spearman (ORR vs. 
med OS) 
rs= -0.26 (-0.64 to 0.11), 
p=0.164 
      
Rose 201066 ORR OS Ovarian 2nd Various 11 407 a) Pearson 
b) Kendall Tau-b 
(ORR vs. med OS) 
a) r=0.56, p=0.071 
 
b) r=0.40, p=0.086 
      
Siddiqui 
201772 
ORR OS Ovarian 2nd + Chemo 31† 9223† a) Pearson, wtd (ORR 
vs. med OS) 
b) Pearson, unwtd 
(ORR vs. med OS) 
a) r=0.82, p<0.001 
b) 0.71, p<0.001 
WLR R2 






b) adj R2=0.66, 
p=NR 
med OS = 9.48 
+ 0.28 * ORR 
Hamada 
201637 
ORR OS Pancreatic 1st Chemo 47 15906† Spearman (ORR vs. 
med OS) 
rs=0.39 (0.20 to 0.55), 
p<0.001 




ORR OS Renal cell Various Immune checkpoint 
inhibitors (PD-(L)1) 
4 1093 Pearson (ORR vs. 
med OS) 
r= -0.40, p=0.436       
Petrelli 
201363 
ORR OS Renal cell 1st Targeted 6† 3188† Spearman, wtd (ORR 
vs. med OS) 
rs=0.96, p<0.0001       
Penel 201462 ORR OS Unknown 
primary 
NR NR 38† NR Pearson via WLR 
(ORR v. med OS) 
r=0.54, p<0.0001       
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Ref SO FO Cancer Line 
Sub-groups 
Treatment N stds N pts Absolute correlation 
methods 
Correlation  coefficient 













ORR OS Urothelial Various Immune checkpoint 
inhibitors (PD-(L)1) 
9 1699 Pearson (ORR vs. 
med OS) 
r= -0.12, p=0.758       
Agarwal 
201419 
ORR OS Urothelial 2nd Chemo or biologic 10 560 Pearson (ORR vs. 
12mo OS) 




b) adj (RE) 
a) R2=0.26, 
p=NR 





ORR OS Urothelial - 2nd 
- Operable 
Chemo NR 214† Pearson (ORR vs. 
12mo OS) 








ORR OS Urothelial - 2nd 
- Metastatic 
Chemo NR 391† Pearson (ORR vs. 
12mo OS) 
r= -0.018, p=NR WLR adj R2 
(ORR vs. 
12mo OS) 
Adj R2= -0.13, 
p=NR 
  
Nie 201960 ORR OS Various 
solid 
tumours 
Various  Immune checkpoint 
inhibitors (PD-(L)1) 
43† 15088†     Squared 
Spearman 







ORR OS Various 
solid 
tumours 
All Immune checkpoint 
inhibitors (PD-(L)1 or 
CTLA4) 
20† 10828† Correlation (NR) 
(ORR vs. 12mo OS) 
r=0.08 (-0.17 to 0.70), 
p=NR 
      
Vidaurre 
200978 
ORR OS Various NR Chemo 85 3982*     Regression 
(NR) (ORR 






ORR OS Various NR Targeted 58 2992*     Regression 
(NR) (ORR 






ORR OS Various NR Chemo or targeted 143† 6794†     Regression 
(NR) (ORR 




CR vs. PFS 
Nickolich 
201459 
CR PFS Lung 
(SCLC) 
- 1st + 2nd + 
maintenance 
- Limited or 
extensive 
Various 66† 8471† Pearson (CR vs. med 
PFS) 
r=0.71, p<0.0001       
Nickolich 
201459 
CR PFS Lung 
(SCLC) 




Various 66† 8471† Pearson (CR vs. med 
PFS) 
r=0.22, p=0.491       
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Ref SO FO Cancer Line 
Sub-groups 
Treatment N stds N pts Absolute correlation 
methods 
Correlation  coefficient 












CR PFS Lung 
(SCLC) 




Various 66† 8471† Pearson (CR vs. med 
PFS) 




CR PFS Multiple 
myeloma  
2nd + Various 79† 13322†     WLR adj R2 
(logit CR vs. 







CR PFS NHL Various Various 73 6071     LR adj R2 
(logit CR vs. 
log med PFS) 
Adj R2=0.57, 
p=NR 
log (med PFS) = 
2.38 + 0.340 * 
logit (CR) 
Zhu 201781 CR PFS NHL 
(indolent; 
follicular) 
NR Chemo, immune or 
targeted 
13 NR     WLR R2: 
a) CR vs. med 
PFS 
b) CR vs. 3-
year PFS 
a) R2=0.69 (0.22 




med PFS = 0.83 
+ 0.46 * CR 
Zhu 201781 CR PFS NHL 
(mantle 
cell) 
NR Chemo, immune or 
targeted 
NR NR     WLR R2 (CR 
vs. med PFS) 
R2=0.39, p=NR   
CR vs. OS 
Agarwal 
201720 
CR OS Acute 
myeloid 
leukemia 
1st Systemic 20† NR     WLR adj R2 
(logit CR vs. 




Pang 201861 CR OS Gastroeso
phageal 
1st + 2nd Targeted 18 7892 Correlation (NR) (CR 
vs. med OS) 
r=0.43, p=0.18       
Li 201949 CR OS Lung 
(NSCLC) 
1st + 2nd Immune checkpoint 
inhibitors 
5* 4103* Pearson (CR vs. med 
OS) 
r=0.19, p=0.75 LR (CR vs. 
med OS) 
R2=0.04, p=NR   
Nickolich 
201459 
CR OS Lung 
(SCLC) 
- 1st + 2nd + 
maintenance 
- Limited or 
extensive 
Various 66† 8471† Pearson (CR vs. med 
OS) 
r=0.62, p<0.0001       
Nickolich 
201459 
CR OS Lung 
(SCLC) 




Various 66† 8471† Pearson (CR vs. med 
OS) 
r=-0.04, p=0.863       
Nickolich 
201459 
CR OS Lung 
(SCLC) 




Various 66† 8471† Pearson (CR vs. med 
OS) 
r=0.19, p=0.295       
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Ref SO FO Cancer Line 
Sub-groups 
Treatment N stds N pts Absolute correlation 
methods 
Correlation  coefficient 










PR (or VGPR or CR) vs. PFS 
Nickolich 
201459 
PR PFS Lung 
(SCLC) 
- 1st + 2nd + 
maintenance 
- Limited or 
extensive 
Various 66† 8471† Pearson (PR vs. med 
PFS) 
r=0.35, p=0.019       
Nickolich 
201459 
PR PFS Lung 
(SCLC) 




Various 66† 8471† Pearson (PR vs. med 
PFS) 
r=0.70, p=0.011       
Nickolich 
201459 
PR PFS Lung 
(SCLC) 




Various 66† 8471† Pearson (PR vs. med 
PFS) 








2nd + Various 79† 13322†     WLR adj R2 
(VGPR or CR 




PR vs. OS 
Nickolich 
201459 
PR OS Lung 
(SCLC) 
- 1st + 2nd + 
maintenance 
- Limited or 
extensive 
Various 66† 8471† Pearson (PR vs. med 
OS) 
r=0.29, p=0.018       
Nickolich 
201459 
PR OS Lung 
(SCLC) 




Various 66† 8471† Pearson (PR vs. med 
OS) 
r=0.60, p=0.009       
Nickolich 
201459 
PR OS Lung 
(SCLC) 




Various 66† 8471† Pearson (PR vs. med 
OS) 
r=0.66, p=0.0002       
*Calculated from reported data. †Unclear for individual subgroups. 
 
adj, adjusted; chemo, chemotherapy; CI, confidence interval; CR, complete response; FO, final outcome; HER2, human epidermal growth factor receptor 2; log, logarithm; LR, linear regression; med, 
median; mo, months; NHL, non-Hodgkin’s lymphoma; NR, not reported; NSCLC, non-small cell lung cancer; ORR, overall response rate (ORR=PR+CR); OS, overall survival; PFS, progression-free 
survival; PR, partial response; r, Pearson correlation; R2, regression coefficient of determination; r2s, squared Spearman rank correlation; rs, Spearman rank correlation; SCLC, small cell lung cancer; SO, 
surrogate outcome; TTP, time to progression; unwtd, unweighted; VGPR, very good partial response; wtd, weighted; WLR, weighted linear regression; WLSR, weighted least squares regression. 
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Supplementary Table 8: Treatment effect correlation and regression results per study 11 
Ref SO FO Cancer Line 
Sub-groups 













STE IQWiG BSES2 
ORR vs. PFS 
Burzykowsk
i 200824 
ORR PFS Breast 1st Chemo 11 3953 Spearman via LR 
with Plackett copula 
(logOR ORR vs. 
logHR PFS) 
rs=0.96 (0.73 to 
1.19), p=NR 
LR   logHR PFS = 
0.10 + 0.50 * 
logOR ORR 
NR Medium+ NE 
Ciani 201526 
Elia 201833 
ORR PFS Colorectal All Systemic 33 NR     LR: Adj R2 (logOR 
ORR vs. logHR PFS) 
Adj R2=0.61 (0.27 
to 0.87), p=NR 
logHR PFS = 
-0.05 - 0.32 * 
logOR ORR 
NR Medium NE 
Ciani 201526 
Elia 201833 
ORR PFS Colorectal - All 
- No crossover 
Systemic 7 NR     LR: Adj R2 (logOR 
ORR vs. logHR PFS) 
Adj R2=0.63 (0.03 
to 0.99), p=NR 
logHR PFS = 
-0.05 - 0.31 * 
logOR ORR 
NR Medium NE 
Tsujino 
201077 
ORR PFS Colorectal NR Targeted 7 NR     LR (unwtd) R2 (diff 
ORR vs. HR PFS) 
R2=0.65, p=0.029 Slope -0.037 NR Medium NE 
Blumenthal 
201722 





25 20013†     WLR R2: 
a) OR ORR vs. HR 
PFS 
b) 6mo ratio ORR vs. 
HR PFS 
a) R2=0.74 (0.55 to 
0.88), p=NR 
b) R2=0.70 (0.50 to 
0.84), p=NR 
  NR Medium+ NE 
Blumenthal 
201521 
ORR PFS Lung 
(NSCLC) 
Various Chemo or 
targeted 
14 12567†     WLR R2 (logOR 
ORR vs. logHR PFS) 
R2=0.89 (0.80 to 
0.98), p=NR 
  NR Medium+ NE 
Blumenthal 
201521 
ORR PFS Lung 
(NSCLC) 
Various Chemo 11 11701†     WLR R2 (logOR 
ORR vs. logHR PFS) 
R2=0.77 (0.58 to 
0.96), p=NR 
  NR Medium+ NE 




6 3752† a) Pearson, wtd 
b) Spearman, wtd 
(OR ORR vs. HR 
PFS) 
a) r= -0.87, 
p<0.0001 
b) rs= -0.97, 
p<0.0001 
WLR R2 (OR ORR 
vs. HR PFS) 
R2=0.76, p=0.011   NR Medium+ Fair 
Ito 201945 ORR PFS Lung 
(NSCLC) 
- Various 






7 1381 a) Pearson, wtd 
b) Spearman, wtd 






WLR R2 (OR ORR 
vs. HR PFS) 
R2=0.45, p=0.101   NR Low Good 
Ritchie 
201865 







8 NR Correlation (NR), 
wtd (OR ORR vs. 
HR PFS) 
r=0.74 (0.38 to 
1.08), p=NR 
      NR Medium Good 
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Ref SO FO Cancer Line 
Sub-groups 













STE IQWiG BSES2 
Roviello 
201767 





7* 3369*     WLR R2 (logOR 
ORR vs. logHR PFS) 
R2=0.42 (0.003 to 
0.85), p=0.06 
  NR Low NE 
Tsujino 
201077 
ORR PFS Lung 
(NSCLC) 
NR Targeted 6 NR     LR (unwtd) R2 (diff 
ORR vs. HR PFS) 




ORR PFS Ovarian 1st Chemo 29 NR Spearman (diff ORR 
vs. diff med PFS) 
rs=0.64, p<0.001 LR R2 (log RR ORR 
vs. log HR PFS) 




ORR PFS Ovarian - 1st 
- Published 
1990-2002 
Chemo 15 NR Spearman (diff ORR 
vs. diff med PFS) 
rs=0.64, p=0.018 LR R2 (log RR ORR 
vs. log HR PFS) 




ORR PFS Ovarian - 1st 
- Published 
2003-2016 
Chemo 16 NR Spearman (diff ORR 
vs. diff med PFS) 
rs=0.58, p=0.019 LR R2 (log RR ORR 
vs. log HR PFS) 
R2=0.53, p=0.003   NR Medium NE 
Siddiqui 
201772 
ORR PFS Ovarian 2nd + Chemo 39† 9223† Pearson, wtd (OR 
ORR vs. HR PFS) 
r=0.42, p=NR    NR Low Poor 
Colloca 
2016a28 
ORR PFS Pancreatic 1st Gemcitabine 
+ chemo or 
targeted 
33* NR Spearman (diff ORR 
vs. diff med PFS) 
rs=0.34, p=NR       NR Low NE 
Colloca 
2016a28 
ORR PFS Pancreatic 1st Gemcitabine 
+ targeted 
14* NR Spearman (diff ORR 
vs. diff med PFS) 
rs=0.25, p=NR       NR Low NE 
Ritchie 
201865 








20† 10828† Correlation (NR), 
wtd (OR ORR vs. 
HR PFS) 
r=0.63 (0.35 to 
0.89), p=NR 
      NR Medium Poor 
Roviello 
201767 






17† 8994†     WLR R2 (logOR 
ORR vs. logHR PFS) 
R2=0.32 (0.02 to 
0.76), p=0.01 




NR Low NE 
Roviello 
201767 







17† 8994†     WLR R2 (logOR 
ORR vs. logHR PFS) 
R2=0.67 (0.02 to 
1.00), p=0.05 
 
NR Medium NE 
Roviello 
201767 







17† 8994†     WLR R2 (logOR 
ORR vs. logHR PFS) 
R2=0.25 (0.02 to 
1.00), p=0.08 
  NR Low NE 
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Ref SO FO Cancer Line 
Sub-groups 













STE IQWiG BSES2 
Tsujino 
201077 
ORR PFS Various 
solid 
tumours 
NR Targeted 17 NR     LR (unwtd) R2 (diff 
ORR vs. HR PFS) 
R2=0.50, p=0.001 Slope -0.022 15% Medium NE 
Wilkerson+
Fojo 200979 
ORR PFS Various 
solid 
tumours 
NR NR 66† NR     LR (unwtd R2): 
a) diff ORR vs. HR 
PFS 






  NR Medium NE 
ORR vs. OS 
Moriwaki 
201656 
ORR OS Biliary tract 1st Chemo 17† 2040     WLR R2 (ratio ORR 
vs. log ratio med OS) 
R2=0.29 (0.01 to 
0.65), p=0.021 
log ratio med 
OS = 0.013 + 
0.282 * ratio 
ORR 
NR Low NE 
Moriwaki 
201656 
ORR OS Biliary tract 1st Chemo 
(gemcitabin
e) 
14† 1880     WLR R2 (ratio ORR 
vs. log ratio med OS) 
R2=0.39 (0.02 to 
0.75), p=0.013 
log ratio med 
OS = 0.020 + 
0.268 * ratio 
ORR 
NR Low NE 
Moriwaki 
201656 
ORR OS Biliary tract 1st Targeted 6† 953     WLR R2 (ratio ORR 
vs. log ratio med OS) 
R2=0.43 (0.03 to 
0.89), p=0.090 
log ratio med 
OS = 0.119 +  
0.155 * ratio 
ORR 
NR Low NE 
Bruzzi 
200523 
ORR OS Breast All Chemo 10 2126     WLR R2: 
a) logOR ORR vs. 
logHR OS 
b) diff ORR vs. diff 
med OS 
a) R2=0.10 (0.00 to 
0.43), p=NR 
b) R2=0.20 (0 to 
0.65), p=NR 
  NR Low NE 
Burzykowsk
i 200824 
ORR OS Breast 1st Chemo 11 3953 Spearman via LR 
with Plackett copula 
(logOR ORR vs. 
logHR OS) 
rs=0.57 (-0.31 to 
1.44), p=NR 
      NR Medium NE 
Hackshaw 
200536 
ORR OS Breast 1st Chemo 42* 9163     WLR R2 (logOR 
ORR vs. logHR OS) 
R2=0.34, p<0.0001 logHR OS = -





NR Low NE 
Hackshaw 
200536 
ORR OS Breast - 1st 
- Recruited 
pre-1990 
Chemo 26* 5244*     WLR R2 (logOR 
ORR vs. logHR OS) 
R2=0.26, p=0.004 Slope 0.28 NR Low NE 
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Ref SO FO Cancer Line 
Sub-groups 













STE IQWiG BSES2 
Hackshaw 
200536 
ORR OS Breast - 1st 
- Recruited 
1990 or after 
Chemo 16* 3919*     WLR R2 (logOR 
ORR vs. logHR OS) 
R2=0.41, p=0.005 Slope 0.24 NR Low NE 
Buyse 
200025 
ORR OS Colorectal 1st Chemo 25 3791     WLR R2 (logOR 
ORR vs. logHR OS) 
R2=0.38 (0.09 to 
0.68), p=NR 
  NR Low NE 
Ciani 201526 
Elia 201833 
ORR OS Colorectal All Systemic 32 NR Spearman (logOR 
ORR vs. logOR OS) 
rs=0.53, p<0.01 a) WLSR R2 (logOR 
ORR vs. logOR OS) 
(timepoint NR) 
b) Adj R2 (logOR 
ORR vs. logHR OS) 
a) R2=0.06 (0.01 to 
0.29), p=NR 
b) Adj R2=0.33 
(0.00 to 0.91), 
p=NR 
logHR OS = -
0.03 - 0.05 * 
logOR ORR 
0.28 Low NE 
Ciani 201526 
Elia 201833 
ORR OS Colorectal - All 
- No crossover 
Systemic 7 NR     LR: Adj R2 (logOR 
ORR vs. logHR OS) 
Adj R2=0.40 (0.00 
to 0.96), p=NR 
logHR OS = -
0.04 - 0.10 * 
logOR ORR 
NR Low NE 
Colloca 
2016b29 
ORR OS Colorectal 1st Bevacizuma
b + chemo 
11 NR Spearman (diff ORR 
vs. diff med OS) 
rs=0.82, p<0.001 LR R2 (diff ORR vs. 
diff med OS) 
R2=0.58, p=0.002   NR Medium NE 
Cremolini 
201731 
ORR OS Colorectal 2nd Targeted 20* 7571 Pearson (via WLR): 
a) rr ORR vs. HR 
OS 
b) diff ORR vs. diff 
med OS 
a) r=0.17, p=0.476 
b) r=0.35, p=0.092 
WLR R2: 
a) rr ORR vs. HR OS 










NR Low NE 
Cremolini 
201731 
ORR OS Colorectal 2nd Targeted, 
anti-
angiogenic 
13* NR Pearson (via WLR): 
a) rr ORR vs. HR 
OS 
b) diff ORR vs. diff 
med OS 
a) r=0.36, p=0.249 
b) r=0.52, p=0.038 
WLR R2: 
a) rr ORR vs. HR OS 










NR Low NE 
Cremolini 
201731 
ORR OS Colorectal 2nd Targeted, 
not anti-
angiogenic 
7* NR Pearson (via WLR): 
a) rr ORR vs. HR 
OS 
b) diff ORR vs. diff 
med OS 
a) r=0.44, p=0.274 
b) r=0.63, p=0.068 
WLR R2: 
a) rr ORR vs. HR OS 










NR Low NE 
Johnson 
200646 
ORR OS Colorectal 1st Chemo 146† 35337†     WLSR R2 (diff ORR 
vs. diff med OS) 
R2=0.10, p<0.0001 Diff med OS 
= 0.340 + 
0.096 * diff 
ORR 
NR Low NE 
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Sidhu 
201373 
ORR OS Colorectal 1st (most) Chemo +/- 
targeted 
24† 20438† Correlation (NR): 
a) OR ORR vs. HR 
OS 
b) Diff ORR vs. HR 
OS 
c) Ratio ORR vs. 
HR OS 
a) r=0.62 (0.37 to 
0.79), p=NR 
b) r=0.64 (0.39 to 
0.79), p=NR 
c) r=0.52 (0.23 to 
0.72), p=NR 
LR (unwtd) R2: 
a) OR ORR vs. HR 
OS 
b) Diff ORR vs. HR 
OS 
c) Ratio ORR vs. HR 
OS 
a) R2=0.39 (0.13 to 
0.62), p=NR 
b) R2=0.41 (0.15 to 
0.63), p=NR 
c) R2=0.27 (0.05 to 
0.52), p=NR 
  NR Medium NE 
Sidhu 
201373 
ORR OS Colorectal 1st (most) Targeted + 
chemo 
13 12060* Correlation (NR): 
a) OR ORR vs. HR 
OS 
b) Diff ORR vs. HR 
OS 
c) Ratio ORR vs. 
HR OS 
a) r=0.50 (0.05 to 
0.75), p=NR 
b) r=0.58 (0.19 to 
0.80), p=NR 
c) r=0.42 (0.00 to 
0.71), p=NR 
LR (unwtd) R2: 
a) OR ORR vs. HR 
OS 
b) Diff ORR vs. HR 
OS 
c) Ratio ORR vs. HR 
OS 
a) R2=0.25 (0.00 to 
0.57), p=NR 
b) R2=0.33 (0.04 to 
0.64), p=NR 
c) R2=0.18 (0.00 to 
0.51), p=NR 
  NR Medium NE 
Sidhu 
201373 
ORR OS Colorectal 1st (most) Targeted 
(anti-EGFR) 
9 7792* Correlation (NR): 
a) OR ORR vs. HR 
OS 
b) Diff ORR vs. HR 
OS 
c) Ratio ORR vs. 
HR OS 
a) r=0.67 (0.27 to 
0.86), p=NR 
b) r=0.72 (0.35 to 
0.88), p=NR 
c) r=0.52 (0.00 to 
0.79), p=NR 
LR (unwtd) R2: 
a) OR ORR vs. HR 
OS 
b) Diff ORR vs. HR 
OS 
c) Ratio ORR vs. HR 
OS 
a) R2=0.45 (0.07 to 
0.74), p=NR 
b) R2=0.52 (0.12 to 
0.78), p=NR 
c) R2=0.27 (0.00 to 
0.62), p=NR 
  NR Medium NE 
Sidhu 
201373 





6* 4916* Correlation (NR): 
a) OR ORR vs. HR 
OS 
b) Diff ORR vs. HR 
OS 
c) Ratio ORR vs. 
HR OS 
a) r=0.68 (0.07 to 
0.89), p=NR 
b) r=0.81 (0.38 to 
0.94), p=NR 
c) r=0.48 (0.00 to 
0.82), p=NR 
LR (unwtd) R2: 
a) OR ORR vs. HR 
OS 
b) Diff ORR vs. HR 
OS 
c) Ratio ORR vs. HR 
OS 
a) R2=0.46 (0.01 to 
0.80), p=NR 
b) R2=0.65 (0.15 to 
0.88), p=NR 
c) R2=0.23 (0.00 to 
0.67), p=NR 
  NR Medium NE 
Tang 200775 ORR OS Colorectal 1st Chemo 39 18668 Spearman (diff ORR 
vs. diff med OS) 
rs=0.39 (0.08 to 
0.63), p=0.015 
      NR Low Poor 
Tsujino 
201077 
ORR OS Colorectal NR Targeted 7 NR     LR (unwtd) R2 (diff 
ORR vs. HR OS) 
R2=0.51, p=0.072 Slope -0.029 NR Medium NE 
Blumenthal 
201722 





25 20013†     WLR R2: 
a) OR ORR vs. HR 
OS 
b) 6mo ratio ORR vs. 
HR OS 
a) R2=0.04 (0.0002 
to 0.28), p=NR 
b) R2=0.05 (0.0001 
to 0.31), p=NR 
  NR Low NE 
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Blumenthal 
201521 
ORR OS Lung 
(NSCLC) 
Various Chemo or 
targeted 
14 12567†     WLR R2 (logOR 
ORR vs. logHR OS) 
R2=0.09 (0 to 0.33), 
p=NR 
  NR Low NE 
Blumenthal 
201521 
ORR OS Lung 
(NSCLC) 
Various Chemo 11 11701†     WLR R2 (logOR 
ORR vs. logHR OS) 
R2=0.44 (0.08 to 
0.80), p=NR 
  NR Low NE 
Hashim 
201839 
ORR OS Lung 
(NSCLC) 
2nd + Various 140 41725 Correlation (NR) via 
WLR: 
a) diff ORR vs. 
logHR OS 
b) diff ORR vs. diff 
med OS 
a) r=0.17 (0.00 to 
0.38), p=NR 
b) r=0.18 (0.02 to 
0.34), p=0.032 
      NA Low NE 
Hashim 
201839 
ORR OS Lung 
(NSCLC) 
- 2nd + 
- Phase III 
Various 59 32348 
 
Correlation (NR) via 
WLR: 
a) diff ORR vs. 
logHR OS 
b) diff ORR vs. diff 
med OS 
a) r=0.37 (0.09 to 
0.60), p=NR 
b) r=0.13 (0.00 to 
0.38), p=0.32 
      NA Low NE 
Hashim 
201839 
ORR OS Lung 
(NSCLC) 
- 2nd + 




Various 54 30654 Correlation (NR) via 
WLR: 
a) diff ORR vs. 
logHR OS 
b) diff ORR vs. diff 
med OS 
a) r=0.40 (0.10 to 
0.63), p=NR 
b) r=0.36 (0.10 to 
0.57), p=0.0074 
      NA Low NE 
Hashim 
201839 
ORR OS Lung 
(NSCLC) 
- 2nd + 
- Phase III 
excl any 
crossover 
Various 38 22574 Correlation (NR) via 
WLR: 
a) diff ORR vs. 
logHR OS 
b) diff ORR vs. diff 
med OS 
a) r=0.52 (0.18 to 
0.75), p=NR 
b) r=0.45 (0.15 to 
0.67), p=0.0051 






ORR OS Lung 
(NSCLC) 
- 2nd + 
- Phase III 
excl crossover 




Various 18 13349 Correlation (NR) via 
WLR: 
a) diff ORR vs. 
logHR OS 
b) diff ORR vs. diff 
med OS 
a) r=0.16 (0.00 to 
0.60), p=NR 
b) r=0.53 (0.08 to 
0.80), p=0.024 




Hotta 201540 ORR OS Lung 
(NSCLC) 
Various Targeted 18 7633†     WLR R2 (OR ORR 
vs. HR OS) 
R2=0.10, p=NR   NR Low NE 
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Targeted 8 NR     WLR R2 (OR ORR 
vs. HR OS) 
R2=0.04, p=NR   NR Low NE 






Targeted 10 NR     WLR R2 (OR ORR 
vs. HR OS) 
R2=0.43, p=NR   NR Low NE 






6 3752† a) Pearson, wtd 
b) Spearman, wtd 
(OR ORR vs. HR 
OS) 
a) r= -0.75, 
p<0.0001 
b) rs= -0.96, 
p<0.0001 
WLR R2 (OR ORR 
vs. HR OS) 
R2=0.57, p=0.051   NR Medium Poor 
Ito 201945 ORR OS Lung 
(NSCLC) 
- Various 






7 1381 a) Pearson, wtd 
b) Spearman, wtd 
(OR ORR vs. HR 
OS) 
a) r= -0.50, 
p<0.0001 
b) rs= -0.21, 
p<0.0001 
WLR R2 (OR ORR 
vs. HR OS) 
R2=0.25, p=0.253   NR Low Fair 
Johnson 
200646 
ORR OS Lung 
(NSCLC) 
1st Chemo 191† 44125†     WLSR R2 (diff ORR 
vs. diff med OS) 
R2=0.16, p<0.0001 Diff med OS 
= -0.048 + 
0.090 * diff 
ORR 
NR Low NE 
Nakashima 
201658 
ORR OS Lung 
(NSCLC) 
1st Chemo 44 22709 Spearman, wtd 
(lnOR ORR vs. HR 
OS) 
rs=0.57, p=NR WLSR adj R2 (lnOR 
ORR vs. lnHR OS) 
Adj R2=0.35, p=NR lnHR OS = -
0.023 -0.133 
x lnOR ORR 
NR Low NE 
Ritchie 
201865 







8 NR Correlation (NR), 
wtd (OR ORR vs. 
HR OS) 
r=0.68 (0.08 to 
1.10), p=NR 
      NR Low Good 
Roviello 
201767 





7* 3369*     WLR R2 (logOR 
ORR vs. logHR OS) 
R2=0.0007 (0.09 to 
0.91), p=0.94 
  NR Low NE 
Tsujino 
201077 
ORR OS Lung 
(NSCLC) 
NR Targeted 5 NR     LR (unwtd) R2 (diff 
ORR vs. HR OS) 
R2=0.84, p=0.030 Slope -0.011 NR Medium+ NE 
Foster 
201134 
ORR OS Lung 
(SCLC) 
1st Chemo 3 (32 
centres
) 
596† Spearman (logOR 
ORR vs. logHR OS) 
rs=0.52, p=NR WLSR R2 (logOR 
ORR vs. logHR OS) 
R2=0.21, p=NR   NR Low NE 
Hotta 200941 ORR OS Lung 
(SCLC) 
1st Chemo 48 8779     WLR R2 (rr ORR vs. 
diff med OS) 
R2=0.33, p=NR Diff med OS 
= 0.00 + 0.06 
* rr ORR 
NR Low NE 
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Hotta 200941 ORR OS Lung 
(SCLC) 
- 1st 
- Clear criteria 
Chemo 43 
comp 
NR     WLR R2 (rr ORR vs. 
diff med OS) 
R2=0.19, p=NR   NR Low NE 







NR     WLR R2 (rr ORR vs. 
diff med OS) 
R2=0.13, p=NR   NR Low NE 







NR     WLR R2 (rr ORR vs. 
diff med OS) 
R2=0.28, p=NR   NR Low NE 







NR     WLR R2 (rr ORR vs. 
diff med OS) 
R2=0.23, p=NR Diff med OS 
= 0.00 + 0.04 
* rr ORR 
NR Low NE 







NR     WLR R2 (rr ORR vs. 
diff med OS) 
R2=0.47, p=NR Diff med OS 
= 0.00 + 0.09 
* rr ORR 




ORR OS Ovarian 1st Chemo 27 NR Spearman (diff ORR 
vs. diff med OS) 
rs=0.41, p=0.035 LR R2 (log RR ORR 
vs. log HR OS) 




ORR OS Ovarian - 1st 
- Published 
1990-2002 
Chemo 13 NR Spearman (diff ORR 
vs. diff med OS) 
rs=0.65, p=0.016 LR R2 (log RR ORR 
vs. log HR OS) 




ORR OS Ovarian - 1st 
- Published 
2003-2016 
Chemo 14 NR Spearman (diff ORR 
vs. diff med OS) 
rs= -0.02, p=0.940 LR R2 (log RR ORR 
vs. log HR OS) 
R2=0.34, p=0.027   NR Low NE 
Siddiqui 
201772 
ORR OS Ovarian 2nd + Chemo 31† 9223†           NR NE NE 
Colloca 
2016a28 
ORR OS Pancreatic 1st Gemcitabine 
+ chemo or 
targeted 
36* NR Spearman (diff ORR 
vs. diff med OS) 
rs=0.29, p=0.067       NR Low NE 
Colloca 
2016a28 
ORR OS Pancreatic 1st Gemcitabine 
+ chemo 
22* NR Spearman (diff ORR 
vs. diff med OS) 
rs=0.23, p=0.250 LR R2 (logRR ORR 
vs. logHR OS) 
R2=0.15, p=NR   NR Low NE 
Colloca 
2016a28 
ORR OS Pancreatic 1st Gemcitabine 
+ targeted 
14* NR Spearman (diff ORR 
vs. diff med OS) 
rs=0.55, p=0.035 LR R2 (logRR ORR 
vs. logHR OS) 
R2=0.28, p=NR   NR Low NE 
Hamada 
201637 
ORR OS Pancreatic 1st Chemo 36 15906† Spearman via 
WLSR (logOR ORR 
vs. logHR OS) 
rs= -0.16 (-0.27 to 
-0.05), p=0.007 
WLSR adj R2 




  NR Low Poor 
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STE IQWiG BSES2 
Makris 
201753 






22* 10379* Pearson (log HR OS 
vs. log OR ORR): 
a) wtd by sample 
size 
b) fixed effect 
c) random effects 
a) r=0.27 (-0.14 to 
0.60), p=0.20 
b) r=0.52 (0.16 to 
0.76), p=0.007 
c) r=0.45 (0.07 to 
0.72), p=0.02 
      NR Low NE 
Makris 
201753 








22* 10379* Pearson (log HR OS 
vs. log OR ORR): 
a) wtd by sample 
size 
b) fixed effect 
c) random effects 
a) r= -0.10 (-0.56 
to 0.40), p=0.70 
b) r=0.16 (-0.34 to 
0.60), p=0.53 
c) r=0.21 (-0.30 to 
0.62), p=0.43 
      NR Low NE 
Makris 
201753 









22* 10379* Pearson (log HR OS 
vs. log OR ORR): 
a) wtd by sample 
size 
b) fixed effect 
c) random effects 
a) r=0.26 (-0.18 to 
0.62), p=0.24 
b) r=0.53 (0.15 to 
0.78), p=0.009 
c) r=0.45 (0.03 to 
0.73), p=0.03 
      NR Low NE 
Colloca 
2016c30 
ORR OS Prostate 1st + 2nd Chemo, 
hormonal + 
targeted 
17 NR Pearson (diff ORR 
vs. diff med OS) 
r=0.38, p=0.132 LR R2 (log RR ORR 
vs. log HR OS) 
R2=0.007, p=0.789   NR Low NE 
Colloca 
2016c30 






5 NR Pearson (diff ORR 
vs. diff med OS) 
r=0.35, p=0.560 LR R2 (log RR ORR 
vs. log HR OS) 
R2=0.53, p=0.275   NR Medium NE 
Colloca 
2016c30 






12 NR Pearson (diff ORR 
vs. diff med OS) 
r=0.41, p=0.185 LR R2 (log RR ORR 
vs. log HR OS) 
R2=0.02, p=0.690   NR Low NE 
Delea 
201232 
ORR OS Renal cell NR Cytokine or 
targeted 
25* 10943† Pearson, wtd (ln(rr) 
ORR vs. -lnHR OS) 
r=0.78, p<0.0001 WLSR adj R2 (ln rr 
ORR vs. -lnHR OS) 
Adj R2=0.59, 
p<0.0001 
-lnHR OS = -
0.11 + 0.30 * 
lnrr ORR 
NR Medium NE 
Petrelli 
201363 
ORR OS Renal cell 1st Targeted 6† 3188† a) Pearson, wtd 
b) Spearman, wtd 
(diff med OS vs. 
diff ORR) 
a) r =0.52, 
p<0.0001 
b) rs = 0.49, 
p<0.0001 
LR R2=0.27, p=NR   NR Low Fair 
Tanaka 
201974 
ORR OS Soft tissue 
sarcoma 
1st Chemo 27† 6156† Kendall's Tau 
(logOR ORR vs. 
logHR OS) 
τ=0.41, p=NR Regression (NR) R2 
(logOR ORR vs. 
logHR OS) 
R2=0.28 (0.02 to 
0.54), p=NR 
  NR Low NE 
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Zer 201680 ORR OS Soft tissue 
sarcoma 
All Systemic 52† 9762† Correlation (NR) via 
WLR (OR ORR vs. 
HR OS) 
r=0.51, p=NR       NR Low NE 
Kaufman 
201847 







27† 10300†     WLR adj R2 (OR 
ORR vs. HR OS) 
Adj R2= -0.07, 
p=0.866 
  NR NE NE 
Kaufman 
201847 







NR NR     WLR adj R2 (OR 
ORR vs. HR OS) 
Adj R2= -0.08, 
p=0.799 
  NR NE NE 
Mushti 
201857 







13 6722     WLR R2 (OR ORR 
vs. HR OS) 
R2=0.13, p=NR   NR Low NE 
Nie 201960 ORR OS Various 
solid 
tumours 




43† 15088†     WLR R2 (lnOR ORR 
vs. lnHR OS) 
R2=0.10, p=0.053   NR Low Poor 
Ritchie 
201865 








20† 10828† Correlation (NR), 
wtd (OR ORR vs. 
HR OS) 
r=0.57 (0.23 to 
0.89), p=NR 
      NR Low Poor 
Roviello 
201767 






17† 8994†     WLR R2 (logOR 
ORR vs. logHR OS) 
R2=0.47 (0.03 to 
0.77), p=0.001 




NR Low NE 
Roviello 
201767 







17† 8994†     WLR R2 (logOR 
ORR vs. logHR OS) 
R2=0.00 (0.00 to 
0.97), p=0.96 
 
NR Low NE 
Roviello 
201767 







17† 8994†     WLR R2 (logOR 
ORR vs. logHR OS) 
R2=0.18 (0.00 to 
0.97), p=0.17 
  NR Low NE 
Tsujino 
201077 
ORR OS Various 
solid 
tumours 
NR Targeted 18 NR     LR (unwtd) R2 (diff 
ORR vs. HR OS) 
R2=0.47, p=0.002 Slope -0.016 21% Low NE 
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Wilkerson+
Fojo 200979 
ORR OS Various 
solid 
tumours 
NR NR 66† NR     LR (unwtd R2): 
a) diff ORR vs. HR 
OS 






  NR Low NE 
CR vs. PFS 
Lee 201148 CR PFS NHL 
(aggressive) 
1st Chemo 12† NR Spearman (diff CR 
vs. diff 3yr PFS) 
rs=0.63 (0.21 to 
0.84), p=0.005 
      NR Medium NE 
Lee 201148 CR PFS NHL 
(indolent) 
1st Chemo 6† NR Spearman (diff CR 
vs. diff 3yr PFS) 
rs=0.41 (-0.52 to 
0.88), p=0.35 
      NR Medium NE 
Shi 201769 CR PFS NHL 
(indolent; 
follicular) 





13 3837     a) WLSR R2 
b) Bivariate Plackett 
copula model 
(logOR CR 30mo vs. 
logHR PFS) 
a) R2WLS=0.88 
(0.77 to 0.96), 
p=NR 
b) R2Copula=0.86 
(0.72 to 1.00), 
p=NR 





1.56 Medium+ NE 








9 2851     a) WLSR R2 
b) Bivariate Plackett 
copula model 
(logOR CR 30mo vs. 
logHR PFS) 
a) R2WLS=0.85 
(0.62 to 0.97), 
p=NR 
b) R2Copula=0.80 
(0.56 to 1.00), 
p=NR 
  NR Medium+ NE 









4 986     a) WLSR R2 
b) Bivariate Plackett 
copula model 
(logOR CR 30mo vs. 
logHR PFS) 
a) R2WLS=0.91 
(0.05 to 1.00), 
p=NR 
b) R2Copula=0.96 
(0.90 to 1.00), 
p=NR 
  NR Medium+ NE 
Shi 201769 CR PFS NHL 
(indolent; 
follicular) 
1st Induction 8 2207     a) WLSR R2 
b) Bivariate Plackett 
copula model 
(logOR CR 30mo vs. 
logHR PFS) 
a) R2WLS=0.89 
(0.75 to 0.98), 
p=NR 
b) R2Copula=0.89 
(0.74 to 1.00), 
p=NR 
  NR Medium+ NE 
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Shi 201769 CR PFS NHL 
(indolent; 
follicular) 
1st Maintenance 5 1630     wtd least squares 
(reported as R2WLS) 
and bivariate Plackett 
copula model 
(reported as 
R2copula), CR30 vs 
PFS 
a) R2WLS=0.93 
(0.84 to 1.00), 
p=NR 
b) R2Copula=0.89 
(0.71 to 1.00), 
p=NR 
  NR Medium+ NE 











9 1415     a) WLSR R2 
b) Bivariate Plackett 
copula model 
(logOR CR 30mo vs. 
logHR PFS) 
a) R2WLS=0.87 
(0.68 to 0.98), 
p=NR 
b) R2Copula=0.73 
(0.42 to 1.00), 
p=NR 
  NR Medium+ NE 












10 1882     a) WLSR R2 
b) Bivariate Plackett 
copula model 
(logOR CR 30mo vs. 
logHR PFS) 
a) R2WLS=0.45 
(0.02 to 0.93), 
p=NR 
b) R2Copula=0.57 
(0.17 to 0.97), 
p=NR 
  NR Low NE 
Shi 201769 CR PFS NHL 
(indolent; 
follicular) 





11 2728     a) WLSR R2 
b) Bivariate Plackett 
copula model 
(logOR CR 24mo vs. 
logHR PFS) 
a) R2WLS=0.84 
(0.63 to 0.95), 
p=NR 
b) R2Copula=0.67 
(0.35 to 0.99), 
p=NR 
logHR PFS = 
0.043 - 0.726 
* logOR 
CR24mo 
NR Medium+ NE 










NR 2585     a) WLSR R2 
b) Bivariate Plackett 
copula model 
(logOR CR 30mo vs. 
logHR PFS) 
a) R2WLS=0.92 
(0.85 to 0.97), 
p=NR 
b) R2Copula=0.94 
(0.87 to 1.00), 
p=NR 




CR PFS Ovarian 1st Chemo 12 NR Spearman (diff RR 
vs. diff med PFS) 
rs=0.19, p=0.555       NR Low NE 
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CR vs. OS 
Hackshaw 
200536 
CR OS Breast 1st Chemo 41* 9163†     WLR R2 (logOR CR 
vs. logHR OS) 
R2=0.12, p=0.02 logHR OS = -
0.0097 + 0.13 
* logOR CR 
 
Slope 0.13 
NR Low NE 
Hackshaw 
200536 
CR OS Breast - 1st 
- Recruited 
pre-1990 
Chemo 26* 5244†     WLR R2 (logOR CR 
vs. logHR OS) 
R2=0.05, p=0.24 Slope 0.09 NR Low NE 
Hackshaw 
200536 
CR OS Breast - 1st 
- Recruited 
1990 or after 
Chemo 15* 3919†     WLR R2 (logOR CR 
vs. logHR OS) 
R2=0.36, p=0.01 Slope 0.16 NR Low NE 
Foster 
201134 
CR OS Lung 
(SCLC) 
1st Chemo 3 (32 
centres
) 
596† Spearman (logOR 
CR vs. logHR OS) 
rs=0.50, p=NR WLSR R2 (logOR 
CR vs. logHR OS) 
R2=0.48, p=NR   NR Low NE 
Lee 201148 CR OS NHL 
(aggressive) 
1st Chemo 36† 16103† Spearman: 
a) diff CR vs. diff 
3yr OS 
b) diff CR vs. diff 
5yr OS 
a) rs=0.58 (0.29 to 
0.77), p=0.004 
b) rs=0.50 (0.23 to 
0.74), p=0.01 
      NR Medium NE 
Lee 201148 CR OS NHL 
(indolent) 
1st Chemo 15† 5128† Spearman: 
a) diff CR vs. diff 
3yr OS 
b) diff CR vs. diff 
5yr OS 
a) rs=0.41 (-0.10 to 
0.74), p=0.098 
b) rs=0.21 (-0.34 
to 0.50), p=0.44 




CR OS Ovarian 1st Chemo 12 NR Spearman (diff pCR 
vs. diff med OS) 
rs=0.42, p=0.180       NR Low NE 
DoR vs. OS 
Colloca 
2016b29 
DoR OS Colorectal 1st Bevacizuma
b + chemo 
5 NR Spearman (diff med 
DoR vs. diff med 
OS) 
rs=0.70, p=0.188       NR Medium NE 
Colloca 
2016a28 
DoR OS Pancreatic 1st Gemcitabine 
+ chemo or 
targeted 
7† NR Spearman (diff med 
DoR vs. diff med 
OS) 
rs=0.76, p=0.049       NR Medium NE 
Colloca 
2016a28 
DoR OS Pancreatic 1st Gemcitabine 
+ chemo 
3† NR Spearman (diff med 
DoR vs. diff med 
OS) 
rs=0.50, p=0.667       NR Low NE 
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Ref SO FO Cancer Line 
Sub-groups 













STE IQWiG BSES2 
Colloca 
2016a28 
DoR OS Pancreatic 1st Gemcitabine 
+ targeted 
4† NR Spearman (diff med 
DoR vs. diff med 
OS) 
rs=0.40, p=0.600       NR Low NE 
*Calculated from reported data. †Unclear for individual subgroups. 
 
adj, adjusted; BSES2, Biomarker-Surrogate Evaluation Schema criteria 2; chemo, chemotherapy; CI, confidence interval; CR, complete response; diff, difference;; DoR, duration of response; FO, final outcome; 
HR, hazard ratio; IQWiG, Institute of Quality and Efficiency in Health Care; ln, natural logarithm; log, logarithm; LR, linear regression; med, median; mo, months; NE, not estimable; NHL, non-Hodgkin’s 
lymphoma; NR, not reported; NSCLC, non-small cell lung cancer; OR, odds ratio; ORR, overall response rate (ORR=PR+CR); OS, overall survival; PFS, progression-free survival; r, Pearson correlation; R2, 
regression coefficient of determination; rs, Spearman rank correlation; rr, relative risk; SCLC, small cell lung cancer; SO, surrogate outcome; STE, surrogate threshold effect; unwtd, unweighted; wtd, weighted; 
WLR, weighted linear regression; WLSR, weighted least squares regression. 
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Supplementary Table 9: Influence of clinical and study factors on association between ORR and OS 13 
Disease and factor comparison Absolute association (r) Treatment effect association (R2) 
Range Factor A Range Factor B Range Factor A Range Factor B 
AML 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Biliary tract 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA 0.43 56 0.29 to 0.39 56 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Breast 
Treatment line: (A) 1st line vs (B) subsequent line 0.61 64 -0.10 to 1.00 51 INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic 0.61 64 -0.10 to 1.00 51 INSUFFICIENT DATA INSUFFICIENT DATA 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA 0.26 to 0.41 36 0.10 to 0.2023 
Colorectal 
Treatment line: (A) 1st line vs (B) subsequent line 0.41 to 0.59 52,75 0.58 35 0.10 to 0.58 25,29,46 0.03 to 0.40 31 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA 0.03 to 0.65 29,31,73,77 0.06 to 0.40 25,26,46 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA 0.58 29 0.38 25 
OS adjustment: (A) adjusted vs (B) unadjusted 
INSUFFICIENT DATA INSUFFICIENT DATA 0.4 26 0.03 to 0.65 
25,26,29,31,46,73,77 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA 0.03 to 0.65 26,29,31,46,73,77 0.38 25 
Gastric and gastroesophageal 
Treatment line: (A) 1st line vs (B) subsequent line 0.18 to 0.47 42 0.38 70 INSUFFICIENT DATA INSUFFICIENT DATA 
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Disease and factor comparison Absolute association (r) Treatment effect association (R2) 
Range Factor A Range Factor B Range Factor A Range Factor B 
Treatment type: (A) targeted vs (B) systemic 0.86 61 0.18 to 0.47 42,70 INSUFFICIENT DATA INSUFFICIENT DATA 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Glioblastoma 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Neuroendocrine 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
NSCLC 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA 0.16 to 0.35 46,58 0.03 to 0.27 39 
Treatment type: (A) targeted vs (B) systemic -0.02 to 0.92 45,49,50,65,71 0.41 to 0.62 68,71 0.0007 to 0.84 40,45,65,67,77 0.16 to 0.44 21,46,58 
Response criteria: (A) RECIST vs (B) WHO 0.52 49 0.62 68 INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted 
INSUFFICIENT DATA INSUFFICIENT DATA 0.03 to 0.27 39 0.0007 to 0.84 
21,22,39,40,45,46,58,65,67,77 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Ovarian 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
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Disease and factor comparison Absolute association (r) Treatment effect association (R2) 
Range Factor A Range Factor B Range Factor A Range Factor B 
Data type: (A) Aggregate vs (B) IPD 0.82 72 0.56 66 INSUFFICIENT DATA INSUFFICIENT DATA 
Pancreatic / adenocarcinoma 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA 0.28 28 0.01 to 0.30 28,37,53 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA 0.01 to 0.04 53 0.07 to 0.30 28,37,53 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Prostate 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Renal / renal cell 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
SCLC 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Soft tissue sarcoma 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
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Disease and factor comparison Absolute association (r) Treatment effect association (R2) 
Range Factor A Range Factor B Range Factor A Range Factor B 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Unknown primary 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Urothelial 
Treatment line: (A) 1st line vs (B) subsequent line INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Treatment type: (A) targeted vs (B) systemic -0.12 18 -0.02 to 0.78 19 INSUFFICIENT DATA INSUFFICIENT DATA 
Response criteria: (A) RECIST vs (B) WHO INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
OS adjustment: (A) adjusted vs (B) unadjusted INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
Data type: (A) Aggregate vs (B) IPD INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA INSUFFICIENT DATA 
AML, acute myeloid leukaemia; IPD, individual patient data; NSCLC, non-small cell lung cancer; r, correlation coefficient (e.g. Pearson or Spearman); R2, 
regression coefficient of determination; SCLC, small cell lung cancer. 
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Surrogate Final Intercept Slope 
ORR to PFS Colorectal52 ORR Median PFS 3.20 0.10 
Lung (NSCLC)76 ORR Median PFS NR 0.07 
Ovarian72 ORR Median PFS 2.59 0.12 
NHL54 log odds 
ORR 
log median PFS 1.97 0.41 
ORR to TTP Gastric42 ORR Median TTP 1.73 0.09 
ORR to OS Colorectal52 ORR Median OS 10.45 0.09 
Lung (NSCLC)76 ORR Median OS NR 0.26 
Ovarian72 ORR Median OS 9.48 0.28 
Gastric42 ORR Median OS 5.89 0.08 
CR to PFS NHL81 CR Median PFS 0.83 0.46 
NHL54 log odds CR log median PFS 2.38 0.34 
CR, complete response; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell lung cancer; 
ORR, overall response rate; OS, overall survival; PFS, progression-free survival; TTP, time to 
progression; VGPR, very good partial response. 
 16 
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Supplementary Table 11: Regression equations for treatment effect (trial-level) associations 18 
Surrogate 
relationship 
Cancer types and 
refs 
Subgroup Based on difference in response Based on relative risk or odds ratio for response 
Surrogate Final Intercept Slope Surrogate Final Intercept Slope 
ORR to PFS Lung (NSCLC)77  Diff ORR HR PFS NR -0.02     
 Colorectal77  Diff ORR HR PFS NR -0.04     
 Various77  Diff ORR HR PFS NR -0.02     
 Colorectal26,33      logOR ORR logHR PFS -0.05 -0.32 
 Breast24      logOR ORR logHR PFS 0.10 0.50 
 Various (immuno)67      logOR ORR logHR PFS -0.13 -0.24 
ORR to OS Colorectal31 - All 
- Anti-angio 
- Non-anti-angio 
Diff ORR Diff median OS NR 0.07 
0.13 
0.14 
    
 Colorectal46  Diff ORR Diff median OS 0.34 0.10     
 Lung (NSCLC)46  Diff ORR Diff median OS -0.05 0.09     
 Colorectal77  Diff ORR HR OS NR -0.03     
 Lung (NSCLC)77  Diff ORR HR OS NR -0.01     
 Various77  Diff ORR HR OS NR -0.02     
 Colorectal26,33 - All 
- No crossover 




 Breast36 - All 
- Recr. pre-1990 
- Recr. 1990 or after 






 Lung (NSCLC)58      lnOR ORR lnHR OS -0.02 -0.13 
 Various (immuno)67      logOR ORR logHR OS -0.13 -0.26 
 Colorectal31 - All 
- Anti-angio 
- Non-anti-angio 
    rr ORR HR OS NR -0.03 
-0.11 
-0.06 
 Renal cell32      ln rr ORR -lnHR OS -0.11 0.30 
 Biliary tract56 - Chemo 
- Gemcitabine 
- Targeted 












Cancer types and 
refs 
Subgroup Based on difference in response Based on relative risk or odds ratio for response 





Lung (SCLC)41 - All 
- Pub. 1990-1996 
- Pub. 1997-2008 






CR to PFS NHL69      logOR CR 30mo logHR PFS -0.09 -0.64 
 NHL69      logOR CR 24mo logHR PFS 0.04 -0.73 
CR to OS Breast36 - All 
- Recr. pre-1990 
- Recr. 1990 or after 






Anti-angio, anti-angiogenic; CR, complete response; diff, difference; HR, hazard ratio; ln, natural logarithm; log, logarithm; NHL, non-Hodgkin’s lymphoma; NR, not reported; 
NSCLC, non-small cell lung cancer; OR, odds ratio; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; pub, published; recr, recruited; rr, relative risk; 
SCLC, small cell lung cancer. 
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Based on difference in response Based on odds ratio for response 
Surrogate Final STE Surrogate Final STE 
ORR to PFS Various77 Diff ORR HR PFS 15%    
ORR to OS Colorectal26    OR ORR OR OS 0.28 
NSCLC39 Diff ORR 
Diff ORR 
HR OS 
Diff median OS 
55% 
41% 
   
Various77 Diff ORR HR OS 21%    
CR to PFS NHL69    OR CR 30mo HR PFS 1.56 
CR, complete response; diff, difference; HR, hazard ratio; NHL, non-Hodgkin’s lymphoma; NSCLC, non-small cell 
lung cancer; OR, odds ratio; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; STE, 









Supplementary Figure 2: BSES2 scores for strength of association across all 202 analyses (within 63 included studies) 25 
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